EP2635114B1 - Irradiation of red blood cells and anaerobic storage - Google Patents
Irradiation of red blood cells and anaerobic storage Download PDFInfo
- Publication number
- EP2635114B1 EP2635114B1 EP11838889.1A EP11838889A EP2635114B1 EP 2635114 B1 EP2635114 B1 EP 2635114B1 EP 11838889 A EP11838889 A EP 11838889A EP 2635114 B1 EP2635114 B1 EP 2635114B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- oxygen
- carbon dioxide
- red blood
- blood cells
- depleted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims description 221
- 238000003860 storage Methods 0.000 title description 123
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 286
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 269
- 239000001301 oxygen Substances 0.000 claims description 269
- 229910052760 oxygen Inorganic materials 0.000 claims description 269
- 239000001569 carbon dioxide Substances 0.000 claims description 143
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 143
- 210000004369 blood Anatomy 0.000 claims description 103
- 239000008280 blood Substances 0.000 claims description 103
- 239000000463 material Substances 0.000 claims description 37
- 239000012528 membrane Substances 0.000 claims description 31
- 239000007789 gas Substances 0.000 claims description 29
- 239000000654 additive Substances 0.000 claims description 28
- 230000000996 additive effect Effects 0.000 claims description 27
- 108010054147 Hemoglobins Proteins 0.000 claims description 24
- 102000001554 Hemoglobins Human genes 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 239000002516 radical scavenger Substances 0.000 claims description 18
- 229940123973 Oxygen scavenger Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 238000011010 flushing procedure Methods 0.000 claims description 13
- 230000001678 irradiating effect Effects 0.000 claims description 11
- 230000000779 depleting effect Effects 0.000 claims description 10
- 210000000265 leukocyte Anatomy 0.000 claims description 7
- 230000036961 partial effect Effects 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 5
- 239000011343 solid material Substances 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 231100000987 absorbed dose Toxicity 0.000 claims description 2
- 239000002594 sorbent Substances 0.000 description 32
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 23
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 23
- 239000000835 fiber Substances 0.000 description 20
- 239000012510 hollow fiber Substances 0.000 description 19
- 230000004888 barrier function Effects 0.000 description 17
- 239000004800 polyvinyl chloride Substances 0.000 description 14
- 239000000306 component Substances 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 229920000915 polyvinyl chloride Polymers 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 230000002000 scavenging effect Effects 0.000 description 13
- 239000003642 reactive oxygen metabolite Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000035699 permeability Effects 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 208000021187 Transfusion associated graft versus host disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 6
- 230000004792 oxidative damage Effects 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 5
- 230000036770 blood supply Effects 0.000 description 5
- 230000002939 deleterious effect Effects 0.000 description 5
- 239000011261 inert gas Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 4
- 239000000920 calcium hydroxide Substances 0.000 description 4
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 4
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000000292 calcium oxide Substances 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229910000000 metal hydroxide Inorganic materials 0.000 description 3
- 150000004692 metal hydroxides Chemical class 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000003846 Carbonic anhydrases Human genes 0.000 description 2
- 108090000209 Carbonic anhydrases Proteins 0.000 description 2
- 239000004803 Di-2ethylhexylphthalate Substances 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 229920012485 Plasticized Polyvinyl chloride Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000006392 deoxygenation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003028 elevating effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003608 radiolysis reaction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 108010083487 hemichrome Proteins 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229920001384 propylene homopolymer Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
- A01N1/142—Apparatus
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
- A01N1/146—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/16—Physical preservation processes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/16—Physical preservation processes
- A01N1/168—Physical preservation processes using electromagnetic fields or radiation; using acoustic waves or corpuscular radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/081—Gamma radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/082—X-rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/10—Apparatus features
- A61L2202/18—Aseptic storing means
- A61L2202/181—Flexible packaging means, e.g. permeable membranes, paper
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/22—Blood or products thereof
Definitions
- the present disclosure relates to a storage blood system having an oxygen/carbon dioxide depletion device and a blood storage bag for the long-term storage of red blood cells (RBCs). More particularly, the present disclosure relates to a blood storage system that is capable of removing oxygen and carbon dioxide from the red blood cells prior to storage and gamma or X-ray irradiating red blood cells post-anaerobic treatment, as well as maintaining oxygen or oxygen and carbon dioxide depleted states during storage, thereby prolonging the storage life and minimizing deterioration of the deoxygenated red blood cells.
- Adequate blood supply and the storage thereof is a problem facing every major hospital and health organization around the world. Often, the amount of blood supply in storage is considerably smaller than the need therefore. This is especially true during crisis periods such as natural catastrophes, war and the like, when the blood supply is often perilously close to running out. It is at critical times such as these that the cry for more donations of fresh blood is often heard. However, unfortunately, even when there is no crisis period, the blood supply and that kept in storage must be constantly monitored and replenished, because stored blood does not maintain its viability for long.
- Hb hemoglobin
- RBCs red blood cells
- transfusion-associated graft-versus-host disease TA-GVHD
- TA-GVHD transfusion-associated graft-versus-host disease
- anaerobically stored RBC must be compatible with gamma- or X-ray irradiation treatment so that anaerobically stored blood can be transfused to patients requiring irradiated RBC.
- Gamma-irradiation abrogates proliferation of T-lymphocytes by damaging the DNA directly and via reactive oxygen species (ROS), namely hydroxyl radicals produced during gamma-radiolysis of water.
- ROS reactive oxygen species
- the major damage observed includes: i) increased hemolysis; ii) increased K+ leak; iii) reduction in post-transfusion survival; and iv) reduced deformability. Such damage is similar to, but an exaggerated form of storage-induced damage of RBC.
- the compromised status of RBC is well known to the physicians who administer such compromised RBC.
- the FDA mandates restricted use of such RBC in terms of shortened shelf life after gamma-irradiation (14 days) and/or 28 days total shelf life for irradiated units.
- irradiation of blood components has received increased attention due to increasing categories of patients eligible to receive such blood to prevent transfusion-associated graft versus host disease.
- irradiation leads to enhancement of storage lesions, which could have deleterious effects when such blood is transfused. It is well known in the field that the main deleterious side-effect of radiation on RBC is oxidative damage caused by ROS.
- Radiation damage to RBC in the presence of oxygen can occur in two ways;
- red blood cell red blood cell
- RBC red blood cell
- studies have shown that irradiated red blood cells that are oxygen and oxygen and carbon dioxide depleted are equivalent or healthier (in terms of K+ leakage, hemolysis and oxidized proteins/lipids) in comparison to non-irradiated and non-oxygen and carbon dioxide depleted blood and non-oxygen and carbon dioxide depleted irradiated blood.
- the higher concentration of potassium in RBC storage media was at levels that indicated red blood cell damage.
- the present disclosure applies the finding of compatibility of gamma-irradiation with anaerobically stored blood, as well as the protective effects of anaerobic conditions in enhancing ATP, DPG and in reducing oxidative damage during refrigerated storage, to substantially reduce the negative or deleterious effect of gamma- and X-ray irradiation of RBCs in the presence of oxygen.
- U.S. Patent No. US Patent 5,362,442 to Kent describes adding a scavenger to bind free radicals such as ethanol.
- U.S. Patent No. 61875572 to Platz et al. describes adding chemical sensitizers;
- U.S. Patent No. 6,403,124, also to Dottori describe adding L-camitine or an alkanoul derivative to reduce RBC cell membrane damage induced by irradiation. These additives are not required to prevent the deleterious effects of irradiation on RBCs when treated anaeorobically.
- a method for storing red blood cells comprising:
- the method may further comprise storing said oxygen depleted or oxygen and carbon dioxide depleted red blood cells before or after said irradiating.
- the method may further comprise leuko-reduction filtering of said red blood cells prior to said step of depleting oxygen or oxygen and carbon dioxide from said red blood cells.
- the method may further comprise adding an additive solution to said red blood cells prior to said step of depleting oxygen or oxygen and carbon dioxide from said red blood cells.
- the said irradiated oxygen depleted or irradiated oxygen and carbon dioxide depleted red blood cells may be stored at a temperature from between about 1°C to about 6°C under anaerobic conditions.
- the said oxygen depleted or irradiated oxygen and carbon dioxide depleted red blood cells may be depleted to an oxygen-saturation of hemoglobin (SO 2 ) level selected from the group consisting of less than 5%, and less than 3% SO 2 .
- SO 2 oxygen-saturation of hemoglobin
- the said depleting comprises passing said red blood cells through an oxygen or oxygen and carbon dioxide depletion device comprising:
- composition comprising:
- a sealed receptacle adapted to retain and store red blood cells comprising irradiated oxygen or oxygen and carbon dioxide depleted red blood cells according to the second aspect of the invention, wherein said sealed receptacle comprises: walls formed from a laminate comprising:
- said oxygen-saturation of hemoglobin (SO 2 ) may be less than 5% or less than 3% SO 2 .
- the said partial pressure of carbon dioxide (pCO 2 ) may be less than 5 mmHg or less than 1 mmHg.
- the said irradiated red blood cells may be depleted of oxygen or oxygen and carbon dioxide using a depletion device comprising:
- the said irradiated oxygen depleted or irradiated oxygen and carbon dioxide depleted red blood cells may further comprise a feature selected from the group consisting of reduced leukocytes relative to an untreated blood sample, an absorbed dose of radiation of between 25 Gray (Gy) to 50 Gy, and an acidic additive solution.
- a method and system is described herein for gamma or X-ray irradiation of RBC under anaerobic or anaerobic and CO 2 depleted conditions, and extended refrigerated storage of such RBC under anaerobic or anaerobic and/or CO 2 depleted conditions using an oxygen and/or CO 2 depletion device.
- a method and system for removing plasma with or without platelets, adding an additive solution (e.g., nutrient and/or metabolic supplements) to the concentrated RBC, filtering out leukocytes and/or platelets via a leuko reduction filter, removing oxygen and/or CO 2 from the filtered RBC, and gamma irradiating or X-ray irradiating the oxygen and/or CO 2 filtered RBC either prior to or during storage thereof.
- an additive solution e.g., nutrient and/or metabolic supplements
- the preferred range of gamma irradiation is a minimum of between about 25 Gy to 50 Gy.
- Gamma or X-ray irradiating RBC under anaerobic or anaerobic and CO 2 conditions (ambient to 1°C) defined as less than 20% SO 2 (oxygen-saturation of hemoglobin), more preferably less than 5%, and most preferably less than 3%.
- Gamma or x-ray irradiating RBC under anaerobic or anaerobic and CO 2 depleted conditions (ambient to 1°C) defined as less than 20% SO 2 (oxygen-saturation of hemoglobin), more preferably SO 2 ⁇ 5%, and most preferably SO 2 ⁇ 3% and pCO 2 ⁇ 10mmHg; pCO 2 ⁇ 5mmHg; pCO 2 ⁇ lmmHg.
- older blood defined as blood stored for more than one week
- oxygen or oxygen and carbon dioxide from such older blood and exposing such blood to Gamma or x-ray irradiation at wherein the levels of oxygen and carbon dioxide are levels defined as less than 20% SO 2 (oxygen-saturation of hemoglobin), more preferably SO 2 ⁇ 5%, and most preferably SO 2 ⁇ 3% and pCO 2 ⁇ 10mmHg; pCO 2 ⁇ 5mmHg; pCO 2 ⁇ lmmHg.
- RBC Storing gamma or X-ray irradiated RBC (either under anaerobic conditions with or without CO 2 depletion) RBC for extended time at 1-6°C under anaerobic or anaerobic and CO 2 depleted condition defined as less than 20% SO 2 (oxygen-saturation of hemoglobin), more preferably less than 5%, and most preferably 3% and less than pCO 2 ⁇ 10mmHg; pCO 2 ⁇ 5mmHg; pCO 2 ⁇ lmmHg.
- a blood storage system comprising: a collection vessel for red blood cells; an oxygen or oxygen/carbon dioxide depletion device; tubing connecting the collection vessel to the oxygen or oxygen/carbon dioxide depletion device and the storage vessel for red blood cells that can be gamma or X-ray irradiated and stored under anaerobic or anaerobic and CO 2 depleted condition for extended time.
- the anaerobic or anaerobic and CO 2 condition is measured as an oxygen-saturation of hemoglobin of less than 20% SO 2 , preferably about 5% or less, and most preferably about 3% or less.
- the oxygen or oxygen/carbon dioxide depletion device described herein comprises: a cartridge; a plurality of gas permeable hollow fibers or sheets extending within the cartridge from an entrance to an exit thereof, wherein the hollow fibers or gas-permeable films are adapted to receiving and conveying red blood cells; and an amount of an oxygen scavenger or both oxygen scavenger and a carbon dioxide scavenger packed within the cartridge and contiguous to and in between the plurality of hollow fibers.
- the oxygen or oxygen/carbon dioxide depletion device described herein comprises: a cartridge; a plurality of hollow fibers or gas-permeable films extending within the cartridge from an entrance to an exit thereof, wherein the hollow fibers or gas-permeable films are adapted to receiving and conveying red blood cells; and a low oxygen or a low oxygen and carbon dioxide environment is created outside the hollow fibers by flowing an inert gas in-between the hollow fibers.
- the blood storage system further comprising a leuko reduction filter disposed between the collection vessel and the oxygen/carbon dioxide depletion device. Also described herein is the blood storage system further comprising an additive solution vessel in communication with the collection vessel. Also described herein is the blood storage system further comprising a plasma vessel in communication with the collection vessel.
- a method for storing red blood cells comprising: removing oxygen or oxygen and carbon dioxide from red blood cells to produce anaerobic red blood cells; and storing irradiated RBC with either gamma- or X-ray, thereby producing irradiated anaerobic red blood cells; and storing the irradiated anaerobic or anaerobic and CO 2 depleted red blood cells.
- the irradiated anaerobic or irradiated anaerobic and CO 2 depleted red blood cells are preferably stored at a temperature from between about 1°C to about 6°C under anaerobic conditions.
- Also described herein is a device and method of removing carbon dioxide (CO 2 ) in addition to oxygen (O 2 ) prior to or at the onset of anaerobic or anaerobic and CO 2 depleted storage and/or gamma or X-ray irradiation.
- CO 2 carbon dioxide
- O 2 oxygen
- Also described herein is a blood collection system that incorporates an oxygen or oxygen/carbon dioxide depletion device having an oxygen or oxygen and carbon dioxide sorbent in combination with a filter or membrane to strip oxygen or oxygen and carbon dioxide from the blood during transport to the storage bag, wherein the oxygen/carbon dioxide depleted blood is gamma or X-ray irradiated either prior to or during storage.
- an oxygen or oxygen/carbon dioxide depletion device having an oxygen or oxygen and carbon dioxide sorbent in combination with a filter or membrane to strip oxygen or oxygen and carbon dioxide from the blood during transport to the storage bag, wherein the oxygen/carbon dioxide depleted blood is gamma or X-ray irradiated either prior to or during storage.
- RBCs do not require oxygen for their own survival. It was shown previously that when RBCs were stored in blood bank refrigerator (1-6°C) under anaerobic or anaerobic and CO 2 depleted conditions, they demonstrated significantly improved post-transfusion recovery after 6-week storage compared to the conventionally stored controls. The mechanisms of reduction in storage lesions under anaerobic or anaerobic/CO 2 depleted conditions have been described and direct evidences demonstrated. It is, at least in part, due to reduction in oxidative damages in the presence of O 2 caused by ROS during refrigerated storage.
- gamma- or X-ray irradiation exacerbate oxidative damage on treated RBC
- storing irradiated RBC under anaerobic and, optionally, CO 2 depleted condition is not expected to intensify the damage; it is also expected to prevent damage resulting from ROS generated during irradiation by depriving O 2 that fuels those reactions.
- Effectiveness of gamma- or X-ray irradiation is not dependent on the presence of oxygen. In contrast, anaerobic condition is shown to be more effective in causing damage to DNA (and thus inhibiting proliferation of lymphocytes). Furthermore, absence of O 2 during and/or immediately after gamma- or X-ray irradiation will reduce O 2 -fueld oxidative damages to RBC induced by hydroxyl radicals and ROS produced by radiolysis of water with gamma-or X-rays.
- a disposable blood anaerobic storage system is shown and referenced using reference numeral 10.
- the blood storage system includes an oxygen/carbon dioxide depletion device 100 (OCDD 100), an anaerobic blood storage bag 200 and an additive solution bag 300.
- OCDD 100 removes oxygen and/or carbon dioxide from red blood cells traveling through it.
- the system also contains a leuko reduction filter 400.
- Components conventionally associated with the process of blood collection are a phlebotomy needle 410, a blood collection bag 420 containing an anti-coagulant and a bag 430 containing plasma.
- Tubing can connect the various components of the blood storage system 10 in various configurations (one instance shown).
- Tube 440 connects collection bag 420 with leuko reduction filter 400.
- Tube 441 connects additive solution bag 300 with collection bag 420.
- Tube 442 connects plasma bag 430 with collection bag 420.
- Tube 443 connects leukoreduction filter 400 with OCDD 100.
- Tube 414 connects OCDD 100 with blood storage bag 200.
- Blood storage system 10 is preferably a single-use, disposable, low cost system. As filtered and oxygen or oxygen and carbon dioxide depleted blood passes from OCDD 100 to blood storage bag 200. Blood stored in bag 200 will be gamma or X-ray irradiated during storage via device 453. Bag 200 containing oxygen depleted or oxygen and carbon dioxide depleted RBC is placed into device 453 and exposed to gamma or X-ray radiation.
- pre-anaerobic blood stored in collection bag 421 can be gamma and/or X-ray irradiated via device 445 before passing through OCDD 100 and stored in bag 200, as shown in Fig. 1b .
- bag 420 could also be gamma and/or X-ray irradiated in an irradiating device 445 prior to passing through leukoreduction filter 400.
- Oxygen or oxygen/carbon dioxide depletion device 100 removes the oxygen from collected RBCs prior to the RBCs being stored in blood storage bag 200.
- the oxygen content in RBCs must be depleted from oxy-hemoglobin because more than 99% of such oxygen is hemoglobin-bound in venous blood.
- the degree of oxygen saturation is to be reduced to less than 4% within 48 hours of blood collection.
- the oxygen depletion is preferably accomplished at room temperature.
- the affinity of oxygen to hemoglobin is highly dependent on the temperature, with a p50 of 26 mmHg at 37° C dropping to -4 mmHg at 4° C.
- carbon dioxide depletion has the beneficial effect of elevating DPG levels in red blood cells.
- Carbon dioxide exists inside RBCs and in plasma in equilibrium with HCO 3 - ion (carbonic acid). Carbon dioxide is mainly dissolved in RBC/plasma mixture as carbonic acid and rapid equilibrium between CO 2 and carbonic acid is maintained by carbonic anhydrase inside RBC. Carbon dioxide is freely permeable through RBC membrane, while HCO 3 - inside RBC and plasma is rapidly equilibrated by anion exchanger (band 3) protein.
- band 3 anion exchanger
- the anaerobic conversion system includes an oxygen or oxygen/carbon dioxide depletion device 515 (OCDD) and an anaerobic blood storage bag 528.
- OCDD 515 removes oxygen or oxygen and carbon dioxide from red blood cells traveling through it.
- Tubing connects the various components of the blood storage system 500.
- Tube 512 connects to RBC concentrate prepared by using an additive solution (e.g., AS1, AS3, AS5, SAGM, MAPS, etc.) and storing in bag 528 by passing aforementioned RBC concentrate from collection bag 510 through OCDD 515.
- an additive solution e.g., AS1, AS3, AS5, SAGM, MAPS, etc.
- Tubes 518 and 520 connect OCDD 515 with blood storage bag 528.
- Blood storage system 500 is preferably a single-use, disposable, low cost system. Oxygen and/or carbon dioxide depleted blood is gamma or X-ray in blood storage bag 528 via device 553 and subsequently stored for later transfusion.
- blood in collection bag 510 may be gamma- or X-ray irradiated via device 551 prior to oxygen or oxygen and carbon dioxide depletion and low temperature storage, as shown in Fig. 2b.
- Fig. 2b applies for reference to the scenario in which blood bag 510 contains older, for example 2 day old blood, that is then irradiated and depleted of oxygen or oxygen and or carbon dioxide, and stored.
- an oxygen or oxygen/carbon dioxide depletion device (OCDD) 101 contains an oxygen sorbent 110.
- OCDD 101 is a disposable cartridge 105 containing oxygen sorbent 110 and a series of hollow fibers 115.
- Oxygen sorbent 110 is a mixture of non-toxic inorganic and/or organic salts and ferrous iron or other materials with high reactivity toward oxygen.
- Oxygen sorbent 110 is made from particles that have significant absorbing capacity for O 2 (more than 5 ml O 2 /g) and can maintain the inside of cartridge 105 to less than 0.01% which corresponds to P0 2 less than 0.08 mmHg.
- Oxygen sorbent 110 is either free or contained in an oxygen permeable envelope.
- OCDD 101 of the present disclosure must deplete approximately 100 mL of oxygen from a unit of blood.
- RBCs are stored in a blood storage bag 200.
- the oxygen content of RBC suspended in additive solution 300 must be reduced to equal to or less than 4% SO 2 before placing them in refrigerated storage. Further, oxygen depleted RBC must be kept in an anaerobic state and low carbon dioxide state throughout entire storage duration.
- RBCs pass through an oxygen permeable film or membrane, that may be formed as hollow fibers 115 of Fig. 3 .
- the membrane or films may be constructed in a flat sheet or hollow fiber form.
- the oxygen permeable films can be non porous materials that are capable of high oxygen permeability rates (polyolefins, silicones, epoxies, polyesters, etc.) and oxygen permeable membranes are hydrophobic porous structures. These may be constructed of polymers (e.g., polyolefins, Teflon, PVDF, or polysulfone) or inorganic materials (e.g., ceramics). Oxygen depletion takes place as RBC pass through hollow fibers 115.
- Oxygen permeable films or oxygen permeable membranes may be extruded into sheets or hollow fibers 15. Accordingly, hollow fibers 115 and sheets may be used interchangeably.
- OCDD provides a simple structure having a large surface area to remove oxygen and maintain constant flow of blood therethrough. The oxygen depletion or removal is accomplished by irreversible reaction of ferrous ion in oxygen sorbent 110 with ambient oxygen to form ferric oxide.
- OCDD 101 does not need agitation for oxygen removal and can be manufactured easily to withstand centrifugation as part of a blood collection system as necessary.
- the depletion devices function to deplete, O 2 and CO 2 , or O 2 alone, or O 2 with specific levels of CO 2 by supplying appropriate composition of flushing gas.
- Gases appropriate for depletion devices are, for example, Ar, He, N 2 , Ar/CO 2 , or N 2 /CO 2 .
- Figs. 9a through 9c and 10a through 910c also disclose scavenging depletion devices.
- Depletion takes place with the use of scavengers or sorbents and without the use of external gases.
- carbon dioxide depletion in conjunction with oxygen depletion is effective to enhance DPG and ATP, respectively, prior to storage in blood storage bags.
- Depletion device 20 includes a plurality of fibers 25, approximately 5000 in number, through which red blood cells flow. Plurality of fibers 25 are surrounded by a plastic cylinder 30. Plastic cylinder or cartridge 30 contains a gas inlet 35 and a gas outlet 40 through which a flushing gas or a combination of flushing gases, such as those mentioned above, are supplied to remove carbon and/or oxygen from blood. Specifications for depletion device 20 are shown in Table 1 below at second column.
- Depletion device 45 like device 20 of Figs. 7a to 7c , includes a plurality of fibers 50, approximately 5000 in number, through which red blood cells flow. Plurality of fibers 50 are surrounded by a plastic cylinder 55. Plastic cylinder 55 contains a gas inlet 60 and a gas outlet 65 through which a gas or a combination of gases, such as those mentioned above are supplied to remove oxygen or oxygen and carbon dioxide from blood. Specifications for depletion device 45 are shown in Table 1 above in the third column. The active surface area of depletion of device 45 is twice that of device 20 because device 45 is twice as long as device 20.
- Figs. 9a through 9c disclose a depletion device 70 having a core 75 containing scavenging materials for either O 2 , or both O 2 and CO 2 .
- Core 75 is packed by a gas permeable film with very low liquid permeability.
- Hollow fibers 80 are wound around core 75, and a plastic cylinder 82 contains and envelopes hollow fibers 80.
- the active surface area for depletion is approximately 0.8796m 2 as shown in Table 2 below at the second column.
- Figs. 10a through 10c disclose a depletion device 85 containing fiber bundles 87 enclosed in gas permeable film with very low liquid permeability. Fiber bundles 87 are surrounded by scavenger materials 89 for either O 2 or both O 2 and CO 2 . Fiber bundles 87 and scavenger materials 89 are contained within a plastic cylinder 90.
- the active surface area for depletion is approximately 0.8796m 2 as shown in Table 2 above at the third column.
- Fig. 11 is a plot of the performance of flushing depletion devices 20 and 45 and scavenging depletion devices 70 and 85.
- the data of Fig. 11 was plotted using the following conditions: Hematocrit, 62% (pooled 3 units of pRBC), and 21°C at various head heights to produce different flow rates.
- Oxygen/carbon dioxide scavenger Multisorb Technologies, Buffalo, NY was activated with adding 5% and 12% w/w water vapor for device 79 and device 85, respectively.
- Data are plotted with flow rate (g RBC suspension per min) vs. pO 2 (mmHg).
- a plurality of gas permeable films/membranes may be substituted for the plurality of hollow fibers.
- the films and fibers may be packed in any suitable configuration within the cartridge, such as linear or longitudinal, spiral, or coil, so long as they can receive and convey red blood cells.
- Fig. 11 shows that lowest oxygen saturation is achieved using devices 45 and 85.
- Device 45 exhibits a larger active surface area exposed to gases along length of fibers 50.
- Device 85 also has a long surface area of exposure to scavenging materials.
- Device 85 has bundles 87 surrounded by scavenging materials 89. The space occupied by scavenging materials 89 between bundles 87 promotes dispersion of oxygen and carbon dioxide from red blood cells contained in fiber bundles 87, thus aiding scavenging of oxygen and carbon dioxide from red blood cells.
- a further use of the depletion devices is to add back oxygen and or carbon dioxide prior to transfusion by flushing with pure oxygen or air. This use is for special cases, such as massive transfusions, where the capacity of the lung to re-oxygenate transfused blood is not adequate, or sickle cell anemia.
- depletion devices can be used to obtain intermediate levels or states of depletion of oxygen and carbon dioxide depending needs of the patient to obtain optimal levels in the transfused blood depending upon the patients needs.
- Blood bag 200 has an inner blood-compatible bag 250 (preferably polyvinyl chloride (PVC)), and an outer barrier film bag 255.
- the material of bag 250 is compatible with RBCs.
- Disposed between inner bag 250 and outer oxygen barrier film bag 255 is a pocket that contains an oxygen/carbon dioxide sorbent 110.
- Barrier film bag 255 is laminated to the entire surface of inner bag 250.
- Sorbent 110 is contained in a sachet 260, which is alternately referred to as a pouch or pocket. Sorbent 110 is optimally located between tubing 440 that leads into and from bag 200, specifically between inner bag and outer oxygen barrier film bag 255.
- Oxygen sorbent is ideally located in a pouch or pocket 260 and not in contact with RBCs. Oxygen sorbent may also be combined with CO 2 scavengers or sorbents, enabling sorbent 110 to deplete both oxygen and carbon dioxide at the same time.
- blood storage bags 201 and 202 are configured to store RBCs for extended storage periods of time.
- Inner blood storage bags 205 are preferably made from DEHP-plasticized PVC and are in contact with RBCs.
- DEHP-plasticized PVC is approximately 200 fold less permeable to oxygen compared to silicone.
- PVC is insufficient as an oxygen barrier to maintain the anaerobic state of RBCs throughout the storage duration. Therefore, blood storage bags 201 and 202 are fabricated with outer transparent oxygen barrier film 206 (e.g., nylon polymer) laminated to the outer surface inner blood bag 205.
- outer transparent oxygen barrier film 206 e.g., nylon polymer
- a small sachet 210 containing oxygen/carbon dioxide sorbent 110 enveloped in oxygen-permeable, RBC compatible membrane is enclosed inside of laminated PVC bag 205 and in contact with RBCs.
- Small sachet envelope 210 is preferably made from a silicone or siloxane material with high oxygen permeability of biocompatible material.
- Sachet envelope 210 has a wall thickness of less than 0.13 mm thickness ensures that O 2 permeability ceases to become the rate-limiting step.
- PVC bag 205 may also contain carbon dioxide scavengers.
- bag 202 has a similar configuration to bag 201 of Fig. 4a .
- bag 202 has a large sorbent 215 enclosed inside of PVC bag 205.
- Large sorbent 215 preferably has a comb-like configuration to rapidly absorb oxygen during extended storage.
- the benefit of laminated bags of Figs. 4a and 4b is that once RBCs are anaerobically stored in bags, no further special handling is required.
- bag 202 may contain carbon dioxide scavenger to provide carbon dioxide-scavenging in addition to oxygen-scavenging capability.
- RBCs are stored in secondary bags 301 and 302, respectively, in order to maintain an anaerobic storage environment for RBC storage.
- Secondary bags 301 and 302 are transparent oxygen barrier films (e.g., nylon polymer) that compensate for the inability of PVC blood bags 305 and 320, respectively, to operate as a sufficient oxygen barrier to maintain RBCs in an anaerobic state.
- Secondary bags 301 and 302 are made with an oxygen barrier film, preferably a nylon polymer or other transparent, flexible film with low oxygen permeability.
- a small oxygen/carbon dioxide sorbent 310 is disposed between a PVC barrier bag 305 and secondary bag 306 to remove slowly diffusing oxygen.
- Fig. 6a is similar to the preferred disclosureof the blood bag of Fig. 4 except that secondary bag 306 is separate from and not bonded to bag 305 in this instance.
- PVC bag 305 including ports are enclosed in secondary barrier bag 305.
- Oxygen sorbent 310 may optionally contain carbon dioxide scavengers to provide both oxygen and carbon dioxide scavenging capability.
- a secondary bag 302 contains a large sachet 325 inside of PVC bag 320.
- Sachet 325 is filled with either oxygen or oxygen/carbon dioxide sorbent 110.
- Sachet 325 is a molded element with surface texture to increase the surface area.
- Sachet 325 has a comb-like geometry for rapid oxygen or oxygen/carbon dioxide depletion.
- Sachet 325 acts rapidly to strip oxygen or oxygen/carbon dioxide from RBCs prior to refrigeration and storage of RBCs in place of OCDD of Fig. 3 .
- agitation is necessary, therefore sachet 325 must possess a large surface area, high oxygen or oxygen/carbon dioxide permeability and mechanical strength to withstand centrifugation step during component preparation and the prolonged storage.
- Sachet 325 is preferably made from materials such as 0.15 mm thick silicone membrane with surface texture to increase the surface area.
- Sachet 325 may be made from materials such as PTFE or other fluoropolymer.
- Sachet 325 may have a rectangular shape such, such as, for example, a 4" X 6" rectangle, although other sizes are possible, for the anaerobic maintenance.
- Sachet 325 may contain carbon dioxide scavengers in addition to oxygen scavengers to provide oxygen and carbon dioxide scavenging capability.
- Figs. 6a and 6b are easily made from off-shelf components except for sachet 325 of Fig. 6b .
- secondary bags 301 and 302 In order to access RBCs for any testing, secondary bags 301 and 302 must be opened. Unless the unit is transfused within short time, RBC must be re-sealed with fresh sorbent for further storage. (1 day air exposure of storage bag would not oxygenate blood to appreciable degree, since PVC plasticized with DEHP has relatively low permeability to oxygen).
- the PVC bag is preferably formed with the oxygen barrier film, such as a SiO 2 layer formed with the sol-gel method.
- the oxygen barrier film such as a SiO 2 layer formed with the sol-gel method.
- a portion of the sheet material will be sealed on standard heat sealing equipment, such as radio frequency sealers. Materials options may be obtained in extruded sheets and each tested for oxygen barrier, lamination integrity, and seal strength/integrity.
- an additive solution from bag 300 is provided prior to stripping oxygen and carbon dioxide from the RBCs is used.
- the additive solution 300 preferably contains the following composition adenine 2mmol/L; glucose 110 mmol/L; mannitol 55 mmol/L; NaCI 26mmol/L; Na 2 HPO 4 12mmol/L citric acid and a pH of 6.5.
- Additive solution 300 is preferably an acidic additive solution OFAS3, although other similar additive solutions could also be used that are shown to enhance oxygen/carbon dioxide -depleted storage. OFAS3 has shown enhanced ATP levels and good in vivo recovery as disclosed herein. While OFAS3 is a preferred additive solution, other solutions that offer similar functionality could also be used.
- additive solutions used currently in the field such as AS1, AS3, AS5, SAGM, and MAPS can also be used. Additive solutions help to prevent rapid deterioration of RBCs during storage and are typically added prior to RBCs being made anaerobic.
- OCDD and storage bags 100 and 200 can be manufactured independent of other components of the disposable, anaerobic blood storage system (i.e., every item upstream of and including leuko reduction filter 400 in Fig. 1a ).
- oxygen scavenger is a material that irreversibly binds to or combines with oxygen under the conditions of use.
- oxygen can chemically react with some component of the material and be converted into another compound. Any material where the off-rate of bound oxygen is zero can serve as an oxygen scavenger.
- oxygen scavengers include iron powders and organic compounds.
- oxygen sorbent may be used interchangeably herein with oxygen scavenger.
- carbon dioxide scavenger is a material that irreversibly binds to or combines with carbon dioxide under the conditions of use.
- the carbon dioxide can chemically react with some component of the material and be converted into another compound. Any material where the off-rate of bound carbon dioxide is zero can serve as a carbon dioxide scavenger.
- carbon dioxide sorbent may be used interchangeably herein with carbon dioxide scavenger.
- oxygen scavengers and carbon dioxide scavengers are provided by Multisorb Technologies (Buffalo, NY) or Mitsubishi Gas Chemical Co (Tokyo, Japan). Oxygen scavengers may exhibit a secondary functionality of carbon dioxide scavenging. Such materials can be blended to a desired ratio to achieve desired results.
- Carbon dioxide scavengers include metal oxides and metal hydroxides. Metal oxides react with water to produce metal hydroxides. The metal hydroxide reacts with carbon dioxide to form water and a metal carbonate. For example, if calcium oxide is used, the calcium oxide will react with water that is added to the sorbent to produce calcium hydroxide CaO + H 2 O ⁇ Ca(OH) 2 .
- the calcium hydroxide will react with carbon dioxide to form calcium carbonate and water.
- scavengers can be incorporated into storage receptacles and bags in any known form, such as in sachets, patches, coatings, pockets, and packets.
- oxygen removal is completed prior to introduction of the RBCs to the blood storage device, then it can be accomplished by any method known in the art.
- a suspension of RBCs can be repeatedly flushed with an inert gas (with or without a defined concentration of carbon dioxide), with or without gentle mixing, until the desired oxygen and or carbon dioxide content is reached or until substantially all of the oxygen and carbon dioxide has been removed.
- the inert gas can be argon, helium, nitrogen, mixtures thereof, or any other gas that does not bind to the hememoiety of hemoglobin.
- OCDD 101 of Fig. 3 can be used with blood bag of Fig. 4 , 201 of Fig. 5a or 301 of Fig. 6a .
- oxygen is depleted by in-bag sachet 215 of Fig. 6b , it can be stored as in Fig. 6b or oxygen/carbon dioxide -depleted content transferred to the final storage bag such as Fig. 4 , Fig. 5a or Fig. 6a for extended storage.
- Other combinations and configurations are fully within the scope of the present disclosure.
- the present disclosure also provides another description of a blood storage device.
- the device is a sealed receptacle adapted to retain and store red blood cells.
- the receptacle has walls formed from a laminate.
- the laminate has (a) an outer layer of a material substantially impermeable to oxygen or oxygen and carbon dioxide, (b) an inner layer of a material compatible with red blood cells, and (c) an interstitial layer between the outer layer and the inner layer.
- the interstitial layer is of a material having admixed therein an amount of an oxygen scavenger or an oxygen/carbon dioxide scavenger.
- the layers preferably take the form of polymers.
- a preferred polymer for the outer layer is nylon.
- a preferred polymer for inner layer is PVC.
- the polymer of the interstitial layer should provide effective adhesion between the inner and outer layers and provide effective admixture of oxygen scavengers or oxygen/carbon dioxide scavengers therein.
- Useful polymers for the interstitial layer include, for example, olefin polymers, such as ethylene and propylene homopolymers and copolymers, and acrylic polymers.
- the present disclosure also provides another description of a blood storage system.
- the system has a collection bag for red blood cells; a unitary device for depleting oxygen or oxygen and carbon dioxide and reducing leukocytes and/or platelets from red blood cells; a storage bag for red blood cells; and tubing connecting the collection bag to the unitary device and the unitary device to the storage bag.
- a feature of this disclosure is that the functions of depleting oxygen or oxygen and carbon dioxide and reducing leukocytes and/or platelets from red blood cells are combined into a single, unitary device rather than require separate devices.
- unitary device can take the form of a single cartridge. Leukocyte and/or platelet reduction is typically carried out by passing red blood cells through a mesh.
- a mesh can be incorporated into either the flushing or the scavenging oxygen or oxygen/carbon dioxide depletion device disclosed herein.
- the mesh is preferably located within the device so that leukocyte and/or platelet reduction takes place prior to the onset of flushing or scavenging.
- Figs. 12a through 12h show the results of a 3-arm study showing: a control (aerobic OFAS3 with no O 2 or CO 2 depletion), anaerobic OFAS3 (both O 2 and CO 2 depleted with pure Ar), and O 2 only depleted with 95% Ar and 5% CO 2 (CO 2 is not depleted).
- Figs. 12a , 12c , 12e and 12g use the additive solution OFAS3 (200mL; experimental, proprietary) and the plots of Figs 12b , 12d , 12f and 12h , use the AS-3 additive solution. Comparing additive solutions, effects of CO 2 depletion on DPG levels were similar. OFAS3 showed higher ATP when oxygen was depleted ( ⁇ CO 2 ), and O 2 depletion alone showed significant enhancement of ATP compared to aerobic control. AS-3 additive exhibited no significant enhancement of ATP when O 2 alone was depleted.
- Figs. 12a and 12b DPG levels during storage. DPG levels were maintained for over 2 weeks, when CO 2 was removed in addition to oxygen.
- Fig. 12c ATP levels during storage with OFAS3. Highest ATP levels were achieved with OFAS3 RBC when O 2 only was depleted. For O 2 /CO 2 depletion, intermediate levels of ATP were observed compared to the control while very high DPG levels were attained during first 2.5 weeks. Very high levels of ATP may suggest higher rate of 24-hour post transfusion recovery. Therefore, extent of carbon dioxide and oxygen depletion levels may be adjusted to meet the specific requirement of the recipient. DPG levels can be maintained very high (at the expense of ATP) for purposes of meeting acute oxygen demand of recipient.
- ATP levels may allow higher 24-hour recovery rate (lower fraction of non-viable RBC upon transfusion) thereby reducing the quantity of blood needed to be transfused (up to 25% of RBC are non-viable). More importantly, this would benefit chronically transfused patients who may not demand highest oxygen transport efficiency immediately after transfusion (DPG level recovers in body after 8-48 hours) who suffers from toxic iron overloading caused by non-viable RBCs.
- Fig. 12d ATP levels during storage with AS3. Highest ATP levels were achieved with AS3 RBC when O 2 only was depleted. No significant differences in ATP levels where observed with control and O 2 depletion alone.
- Figs. 12e and 12f pH of RBC cytosol (in) and suspending medium (ex). Immediately after gas exchange (day 0), significant rise in pH (in and ex) was observed only when CO 2 was depleted together with O 2 . Rapid rates of pH decline observed with CO 2 / O 2 depleted samples were caused by higher rates of lactate production ( Figs. 12g and 12h ).
- Figs. 12g and 12h Normalized (to hemoglobin) glucose and lactate levels during storage with OFAS3 and AS3. Higher rates of glucose depletion and lactate productions correspond to high DPG levels observed in panels A and B. Legends for symbols/lines are same for both panels. OFAS3 additive contains similar glucose concentration with x2 volume resulting in higher normalized glucose levels.
- Figs. 12a and 12c taken together suggest that extent of increases (compared to control) of ATP and DPG levels may be adjusted by controlling level of CO 2 depletion, when O 2 is depleted. Higher glucose utilization and lactate production were observed with enhanced DPG production ( Fig. 12g ). This may be also effective with AS3 additive, since similar trend in glucose utilization and lactate production were observed ( Fig. 12h ).
- Fig. 13 shows a graph comparing the effect of gamma irradiation on aerobic and anaerobic RBC.
- Fig. 13 shows an control unit, RBC that are aerobic and not gamma-irradiated (Unit A, black filled solid line), aerobic RBC that are gamma-irradiated (Unit B; control plus gamma irradiation indicated by a filled circle with dotted line) and an anaerobically depleted RBC unit that has been gamma-irradiated (Unit C; Anaerobic + ⁇ , open circle and solid line).
- Unit B and Unit C are irradiated and Unit A is non-irradiated and aerobic RBC.
- the constituent of the blood that is being measured is potassium.
- the amount of leakage of potassium (K+) from RBC that is measured in the storage media is an indicator of health of the RBC. Therefore, in the context of the present application, a greater level of concentration of potassium in RBC storage media, is indicative of a greater level of RBC damage relative to a lower level of concentration of potassium in RBC storage media.
- Fig. 13 indicates that gamma irradiation induced a high rate of K+ leakage during the first week for Unit B and Unit C. K+ leakage rates after days eight and fifteen, were similar for all units. Significantly, the difference between K+ leakage between Unit B and Unit C increases beyond the twenty-second day of storage. The results indicate that this trend could exist for several more days. Accordingly, the use of anaerobic depletion and gamma irradiation may permit the extension of current FDA storage limit of twenty-eight days for anaerobically depleted and gamma irradiated blood prepared after component separation.
- Irradiating RBC for immuno-compromised individuals is a necessity.
- the present results show that irradiated RBC that were also oxygen depleted did not increase K+ leakage rates, an indicator of RBC damage.
- the benefits of oxygen depleted RBC including increased levels of ATP and DPG-2,3 are not negatively impacted by the irradiation.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Hematology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Physics & Mathematics (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Thermal Sciences (AREA)
- Electromagnetism (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- External Artificial Organs (AREA)
Description
- The present disclosure relates to a storage blood system having an oxygen/carbon dioxide depletion device and a blood storage bag for the long-term storage of red blood cells (RBCs). More particularly, the present disclosure relates to a blood storage system that is capable of removing oxygen and carbon dioxide from the red blood cells prior to storage and gamma or X-ray irradiating red blood cells post-anaerobic treatment, as well as maintaining oxygen or oxygen and carbon dioxide depleted states during storage, thereby prolonging the storage life and minimizing deterioration of the deoxygenated red blood cells.
- Adequate blood supply and the storage thereof is a problem facing every major hospital and health organization around the world. Often, the amount of blood supply in storage is considerably smaller than the need therefore. This is especially true during crisis periods such as natural catastrophes, war and the like, when the blood supply is often perilously close to running out. It is at critical times such as these that the cry for more donations of fresh blood is often heard. However, unfortunately, even when there is no crisis period, the blood supply and that kept in storage must be constantly monitored and replenished, because stored blood does not maintain its viability for long.
- Stored blood undergoes steady deterioration which is, in part, caused by hemoglobin oxidation and degradation and adenosine triphosphate (ATP) and 2-3,biphosphoglycerate (DPG) depletion. Oxygen causes hemoglobin (Hb) carried by the red blood cells (RBCs) to convert to met-Hb, the breakdown of which produces toxic products such as hemichrome, hemin and free Fe3±. Together with the oxygen, these products catalyze the formation of hydroxyl radicals (OH.cndot.), and both the OH.cndot. and the met-Hb breakdown products damage the red blood cell lipid membrane, the membrane skeleton, and the cell contents. As such, stored blood is considered unusable after 6 weeks, as determined by the relative inability of the red blood cells to survive in the circulation of the transfusion recipient. The depletion of DPG prevents adequate transport of oxygen to tissue thereby lowering the efficacy of transfusion immediately after administration (levels of DPG recover once in recipient after 8-48 hrs). In addition, these deleterious effects also result in reduced overall efficacy and increased side effects of transfusion therapy with stored blood before expiration date, when blood older than two weeks is used. Reduction in carbon dioxide content in stored blood has the beneficial effect of elevating DPG levels in red blood cells.
- There is, therefore, a need to be able to deplete oxygen and carbon dioxide levels in red blood cells prior to storage on a long-term basis without the stored blood undergoing the harmful effects caused by the oxygen and hemoglobin interaction. Furthermore, there is a need to store oxygen and carbon dioxide depleted red blood cells in bags containing or in a bag surrounded by a barrier film with oxygen and carbon dioxide depletion materials. Furthermore, there is a need to optimize ATP and DPG levels in stored red blood cells by varying the depletion or scavenging constituents prior to and/or during storage depending upon the needs of the recipient upon transfusion. Furthermore, the blood storage devices and methods must be simple, inexpensive and capable of long-term storage of the blood supply.
- Another issue relates to transfusion-associated graft-versus-host disease (TA-GVHD) which is a rare but nearly fatal complication associated with transfusion therapy in severely immuno-compromised blood recipients (for example, bone marrow transplant recipient, patients receiving aggressive chemotherapy, premature neonates). Prevention of TA-GVHD requires complete removal of, or arrest of the proliferative potential of T-lymphocytes from donor blood. Although leuko reduction filters are widely in use, they are not adequate in prevention of TA-GVHD because it cannot completely eliminate lymphocytes. Thus, lymphocyte inactivation by gamma-irradiation is currently the only recommended method for TA-GVHD prevention. Since it is a nearly fatal side effect of transfusion, some hospitals and countries irradiate every unit of RBC for TA-GVHD prevention. More commonly, RBC units ordered for specific recipients are irradiated before dispensed to the bedside.
- Accordingly, anaerobically stored RBC must be compatible with gamma- or X-ray irradiation treatment so that anaerobically stored blood can be transfused to patients requiring irradiated RBC.
- Gamma-irradiation abrogates proliferation of T-lymphocytes by damaging the DNA directly and via reactive oxygen species (ROS), namely hydroxyl radicals produced during gamma-radiolysis of water. Although red blood cells (RBC) do not contain DNA, ROS generated by gamma-irradiation have been shown to cause significant damage to the RBC. The major damage observed includes: i) increased hemolysis; ii) increased K+ leak; iii) reduction in post-transfusion survival; and iv) reduced deformability. Such damage is similar to, but an exaggerated form of storage-induced damage of RBC. The compromised status of RBC is well known to the physicians who administer such compromised RBC. The FDA mandates restricted use of such RBC in terms of shortened shelf life after gamma-irradiation (14 days) and/or 28 days total shelf life for irradiated units.
- The irradiation of blood components has received increased attention due to increasing categories of patients eligible to receive such blood to prevent transfusion-associated graft versus host disease. However, irradiation leads to enhancement of storage lesions, which could have deleterious effects when such blood is transfused. It is well known in the field that the main deleterious side-effect of radiation on RBC is oxidative damage caused by ROS.
- Radiation damage to RBC in the presence of oxygen can occur in two ways;
- i) By ROS generated during and immediately after irradiation. ROS can reside in RBC lipid, then attack proteins and lipids in vicinity later during storage, as well as to initiate peroxidation cycle of lipid and protein using oxygen to fuel.
- ii) Met-Hb and its denaturation products generated in i) above act as catalysts to further cause ROS-mediated oxidative damage during subsequent extended refrigerated storage of RBC. This is an enhanced version of storage lesion development using O2.
- On the other hand, there is ample literature suggesting ROS as a major culprit in causing deterioration of red blood cell (RBC) during refrigerated storage at blood banks, and that storing RBC under anaerobic condition significantly reduce such damages. Studies have shown that irradiated red blood cells that are oxygen and oxygen and carbon dioxide depleted are equivalent or healthier (in terms of K+ leakage, hemolysis and oxidized proteins/lipids) in comparison to non-irradiated and non-oxygen and carbon dioxide depleted blood and non-oxygen and carbon dioxide depleted irradiated blood. In the context of the present application, the higher concentration of potassium in RBC storage media was at levels that indicated red blood cell damage. The present disclosure applies the finding of compatibility of gamma-irradiation with anaerobically stored blood, as well as the protective effects of anaerobic conditions in enhancing ATP, DPG and in reducing oxidative damage during refrigerated storage, to substantially reduce the negative or deleterious effect of gamma- and X-ray irradiation of RBCs in the presence of oxygen.
- U.S. Patent No.
US Patent 5,362,442 to Kent describes adding a scavenger to bind free radicals such as ethanol.U.S. Patent No. 61875572 to Platz et al. U.S. Patent No. 6,482,585 to Dottori andU.S. Patent No. 6,403,124, also to Dottori , describe adding L-camitine or an alkanoul derivative to reduce RBC cell membrane damage induced by irradiation. These additives are not required to prevent the deleterious effects of irradiation on RBCs when treated anaeorobically. - S. Holme in Transfusion and Apheresis Science, 33, (2005) 55-61 describes issues relating to the quality of stored red blood cells (RBCs) including storage lesion, use of gamma irradiation and storage in containers of plastic made with non-leachable plasticizers. T. Yoshida and S. Shevkoplyas in Blood Transfusion, 8, (2010) 220-236, describes anaerobic storage of red blood cells. Agarwal et al in Indian J. Med. Res., 122, (2005) 385-387 describes effect of pre-storage gamma irradiation on red blood cells.
- Aspects of the invention for which protection is sought are defined in the claims.
- According to a first aspect of the invention, there is provided a method for storing red blood cells comprising:
- depleting oxygen or oxygen and carbon dioxide from red blood cells, thereby producing oxygen depleted or oxygen and carbon dioxide depleted red blood cells; and
- irradiating said oxygen depleted or oxygen and carbon dioxide depleted red blood cells with either gamma or X-ray irradiation, thereby producing irradiated oxygen depleted or irradiated oxygen and carbon dioxide depleted red blood cells,
- wherein said oxygen depleted red blood cells comprise an oxygen-saturation of hemoglobin (SO2) level of less than 20% and said oxygen and carbon dioxide depleted red blood cells comprise a partial pressure of carbon dioxide (pCO2) of less than 10 mmHg.
- The method may further comprise storing said oxygen depleted or oxygen and carbon dioxide depleted red blood cells before or after said irradiating.
- The method may further comprise leuko-reduction filtering of said red blood cells prior to said step of depleting oxygen or oxygen and carbon dioxide from said red blood cells.
- The method may further comprise adding an additive solution to said red blood cells prior to said step of depleting oxygen or oxygen and carbon dioxide from said red blood cells.
- In the above method the said irradiated oxygen depleted or irradiated oxygen and carbon dioxide depleted red blood cells may be stored at a temperature from between about 1°C to about 6°C under anaerobic conditions.
- In the above method the said oxygen depleted or irradiated oxygen and carbon dioxide depleted red blood cells may be depleted to an oxygen-saturation of hemoglobin (SO2) level selected from the group consisting of less than 5%, and less than 3% SO2.
- In the above method the said depleting comprises passing said red blood cells through an oxygen or oxygen and carbon dioxide depletion device comprising:
- a) a cartridge;
a plurality of gas-permeable films or membranes extending within the cartridge from an entrance to an exit thereof, wherein said plurality of gas-permeable films or membranes are adapted to receiving and conveying red blood cells; and
an amount of an oxygen scavenger or an oxygen and a carbon dioxide scavenger packed within said cartridge and contiguous to and in between said plurality of gas-permeable films or membranes; or - b) a receptacle of a solid material having an inlet and an outlet adapted to receiving and expelling a flushing gas and
a plurality of gas-permeable films or membranes extending within said receptacle from an entrance to an exit thereof, wherein said plurality of gas-permeable films or membranes are formed of a material permeable to oxygen and are adapted to receiving and conveying red blood cells. - According to a second aspect of the invention, there is provided a composition comprising:
- irradiated oxygen or oxygen and carbon dioxide depleted red blood cells,
- wherein said oxygen depleted red blood cells comprise an oxygen-saturation of hemoglobin (SO2) level of less than 20% and said oxygen and carbon dioxide depleted red blood cells comprise an oxygen-saturation of hemoglobin (SO2) level of less than 20% and a partial pressure of carbon dioxide (pCO2) of less than 10 mmHg.
- According to a third aspect of the invention, there is provided a sealed receptacle adapted to retain and store red blood cells comprising irradiated oxygen or oxygen and carbon dioxide depleted red blood cells according to the second aspect of the invention, wherein said sealed receptacle comprises:
walls formed from a laminate comprising: - an outer layer of a material substantially impermeable to oxygen or oxygen and carbon dioxide;
- an inner layer of a material compatible with red blood cells; and
- an interstitial layer between said outer layer and said inner layer,
- wherein the interstitial layer is of a material having admixed therein an oxygen or oxygen and carbon dioxide scavenger.
- In the composition according to the second aspect of the invention, said oxygen-saturation of hemoglobin (SO2) may be less than 5% or less than 3% SO2. The said partial pressure of carbon dioxide (pCO2) may be less than 5 mmHg or less than 1 mmHg. The said irradiated red blood cells may be depleted of oxygen or oxygen and carbon dioxide using a depletion device comprising:
- a) a cartridge;
a plurality of gas-permeable films or membranes extending within the cartridge from an entrance to an exit thereof, wherein said plurality of gas-permeable films or membranes are adapted to receiving and conveying red blood cells; and
an amount of an oxygen scavenger or an oxygen and a carbon dioxide scavenger packed within said cartridge and contiguous to and in between said plurality of gas-permeable films or membranes; or - b) a receptacle of a solid material having an inlet and an outlet adapted to receiving
and expelling a flushing gas and
a plurality of gas-permeable films or membranes extending within said receptacle from an entrance to an exit thereof, wherein said plurality of gas-permeable films or membranes are formed of a material permeable to oxygen and are adapted to receiving and conveying red blood cells. - In the composition according to the second aspect of the invention, the said irradiated oxygen depleted or irradiated oxygen and carbon dioxide depleted red blood cells may further comprise a feature selected from the group consisting of reduced leukocytes relative to an untreated blood sample, an absorbed dose of radiation of between 25 Gray (Gy) to 50 Gy, and an acidic additive solution.
- A method and system is described herein for gamma or X-ray irradiation of RBC under anaerobic or anaerobic and CO2 depleted conditions, and extended refrigerated storage of such RBC under anaerobic or anaerobic and/or CO2 depleted conditions using an oxygen and/or CO2 depletion device.
- A method and system is described herein for removing plasma with or without platelets, adding an additive solution (e.g., nutrient and/or metabolic supplements) to the concentrated RBC, filtering out leukocytes and/or platelets via a leuko reduction filter, removing oxygen and/or CO2 from the filtered RBC, and gamma irradiating or X-ray irradiating the oxygen and/or CO2 filtered RBC either prior to or during storage thereof. The preferred range of gamma irradiation is a minimum of between about 25 Gy to 50 Gy.
- Gamma or X-ray irradiating RBC under anaerobic or anaerobic and CO2 conditions (ambient to 1°C) defined as less than 20% SO2 (oxygen-saturation of hemoglobin), more preferably less than 5%, and most preferably less than 3%.
- Storing gamma or X-ray irradiated (either under anaerobic or anaerobic and CO2 conditions) RBC for extended time at 1-6°C under anaerobic condition defined as less than 20% SO2 (oxygen-saturation of hemoglobin), more preferably less than 5%, and most preferably less than 3%.
- Gamma or x-ray irradiating RBC under anaerobic or anaerobic and CO2 depleted conditions (ambient to 1°C) defined as less than 20% SO2 (oxygen-saturation of hemoglobin), more preferably SO2 < 5%, and most preferably SO2 <3% and pCO2 <10mmHg; pCO2<5mmHg; pCO2<lmmHg.
- Using older blood, defined as blood stored for more than one week, and removing oxygen or oxygen and carbon dioxide from such older blood and exposing such blood to Gamma or x-ray irradiation at wherein the levels of oxygen and carbon dioxide are levels defined as less than 20% SO2 (oxygen-saturation of hemoglobin), more preferably SO2 < 5%, and most preferably SO2 <3% and pCO2 <10mmHg; pCO2<5mmHg; pCO2<lmmHg.
- Storing gamma or X-ray irradiated RBC (either under anaerobic conditions with or without CO2 depletion) RBC for extended time at 1-6°C under anaerobic or anaerobic and CO2 depleted condition defined as less than 20% SO2 (oxygen-saturation of hemoglobin), more preferably less than 5%, and most preferably 3% and less than pCO2 <10mmHg; pCO2<5mmHg; pCO2<lmmHg.
- Also described herein is a blood storage system comprising: a collection vessel for red blood cells; an oxygen or oxygen/carbon dioxide depletion device; tubing connecting the collection vessel to the oxygen or oxygen/carbon dioxide depletion device and the storage vessel for red blood cells that can be gamma or X-ray irradiated and stored under anaerobic or anaerobic and CO2 depleted condition for extended time.
- The anaerobic or anaerobic and CO2 condition is measured as an oxygen-saturation of hemoglobin of less than 20% SO2, preferably about 5% or less, and most preferably about 3% or less.
- The oxygen or oxygen/carbon dioxide depletion device described herein comprises: a cartridge; a plurality of gas permeable hollow fibers or sheets extending within the cartridge from an entrance to an exit thereof, wherein the hollow fibers or gas-permeable films are adapted to receiving and conveying red blood cells; and an amount of an oxygen scavenger or both oxygen scavenger and a carbon dioxide scavenger packed within the cartridge and contiguous to and in between the plurality of hollow fibers.
- Preferably, the oxygen or oxygen/carbon dioxide depletion device described herein comprises: a cartridge; a plurality of hollow fibers or gas-permeable films extending within the cartridge from an entrance to an exit thereof, wherein the hollow fibers or gas-permeable films are adapted to receiving and conveying red blood cells; and a low oxygen or a low oxygen and carbon dioxide environment is created outside the hollow fibers by flowing an inert gas in-between the hollow fibers.
- Also described herein is the blood storage system further comprising a leuko reduction filter disposed between the collection vessel and the oxygen/carbon dioxide depletion device. Also described herein is the blood storage system further comprising an additive solution vessel in communication with the collection vessel. Also described herein is the blood storage system further comprising a plasma vessel in communication with the collection vessel.
- A method is described herein for storing red blood cells, the method comprising: removing oxygen or oxygen and carbon dioxide from red blood cells to produce anaerobic red blood cells; and storing irradiated RBC with either gamma- or X-ray, thereby producing irradiated anaerobic red blood cells; and storing the irradiated anaerobic or anaerobic and CO2 depleted red blood cells.
- The irradiated anaerobic or irradiated anaerobic and CO2 depleted red blood cells are preferably stored at a temperature from between about 1°C to about 6°C under anaerobic conditions.
- Also described herein is a device and method of removing carbon dioxide (CO2) in addition to oxygen (O2) prior to or at the onset of anaerobic or anaerobic and CO2 depleted storage and/or gamma or X-ray irradiation.
- Also described herein is a blood collection system that incorporates an oxygen or oxygen/carbon dioxide depletion device having an oxygen or oxygen and carbon dioxide sorbent in combination with a filter or membrane to strip oxygen or oxygen and carbon dioxide from the blood during transport to the storage bag, wherein the oxygen/carbon dioxide depleted blood is gamma or X-ray irradiated either prior to or during storage.
- The present disclosure and its features and advantages will become more apparent from the following detailed description with reference to the accompanying drawings.
-
-
Fig. 1a illustrates the components of a gamma irradiated, disposable blood anaerobic storage system of the present disclosure. -
Fig. 1b illustrates the components of a second gamma irradiated, disposable blood anaerobic storage system of the present disclosure. -
Fig. 2a illustrates the components of a disposable blood anaerobic storage system that are used in conjunction with RBC irradiation in which red blood cells are irradiated during anaerobic storage. -
Fig. 2b illustrates the components of a disposable blood anaerobic storage system that are used in conjunction with RBC irradiation. -
Fig. 3 illustrates a pre-storage oxygen/carbon dioxide depletion device of the present disclosure. -
Fig. 4 illustrates a blood storage bag having a storage bag with a secondary outer oxygen film containing an oxygen sorbent in a pocket. -
Fig. 5a illustrates a pre-storage oxygen/carbon dioxide depletion bag having a blood storage bag with a large sorbent sachet enclosed in gas-permeable, red blood cell compatible polymers in contact with the RBCs. -
Fig. 5b illustrates a blood storage bag having a storage bag a laminated oxygen film barrier with a large sorbent in contact with the RBCs. -
Fig. 6a illustrates a blood storage bag having a secondary configured secondary outer barrier bag surrounding an inner blood storage bag having an oxygen sorbent. -
Fig. 6b illustrates a blood storage bag having a secondary outer barrier bag surrounding an inner blood storage bag having a large oxygen sorbent sachet enclosed in a gas permeable, red blood cell compatible polymers in contact with RBCs. -
Figs. 7a through 7c illustrate a depletion device that depletes oxygen and carbon dioxide from red blood cells prior to storage by a flushing inert gas or inert gas /CO2 mixture of defined composition around a hollow fiber inside the assembly. -
Figs. 8a through 8c illustrate another depletion device that depletes oxygen and carbon dioxide from red blood cell prior to storage. -
Figs. 9a through 9c illustrate another a depletion device that depletes oxygen and carbon dioxide from red blood cells prior to storage wherein oxygen and CO2 is scavenged by scavenger materials in the core of the cylinder, surrounded by hollow fibers. -
Figs. 10a through 10c illustrate another depletion device that depletes oxygen and carbon dioxide from red blood cells prior to storage wherein oxygen and CO2 is scavenged by scavenger materials surrounding cylinders of hollow fibers enveloped in gas permeable, low water vapor transmission material. -
Fig. 11 illustrates a plot of flow rate of RBC suspension per minute versus oxygen partial pressure for the depletion devices ofFigs. 7a through 7c ,Figs. 8a through 8c ,Figs. 9a through 9c andFigs. 10a through 10c . -
Figs 12a through 12h illustrate plots of the effect of oxygen and oxygen and carbon dioxide depletion on metabolic status of red blood cells during
refrigerated storage. -
Fig 13 illustrates an effect of gamma-irradiation on K+ leak rates from RBC (as measured by free K+ concentrations in RBC suspending media after storage). - RBCs do not require oxygen for their own survival. It was shown previously that when RBCs were stored in blood bank refrigerator (1-6°C) under anaerobic or anaerobic and CO2 depleted conditions, they demonstrated significantly improved post-transfusion recovery after 6-week storage compared to the conventionally stored controls. The mechanisms of reduction in storage lesions under anaerobic or anaerobic/CO2 depleted conditions have been described and direct evidences demonstrated. It is, at least in part, due to reduction in oxidative damages in the presence of O2 caused by ROS during refrigerated storage.
- Because gamma- or X-ray irradiation exacerbate oxidative damage on treated RBC, storing irradiated RBC under anaerobic and, optionally, CO2 depleted condition is not expected to intensify the damage; it is also expected to prevent damage resulting from ROS generated during irradiation by depriving O2 that fuels those reactions.
- Effectiveness of gamma- or X-ray irradiation is not dependent on the presence of oxygen. In contrast, anaerobic condition is shown to be more effective in causing damage to DNA (and thus inhibiting proliferation of lymphocytes). Furthermore, absence of O2 during and/or immediately after gamma- or X-ray irradiation will reduce O2-fueld oxidative damages to RBC induced by hydroxyl radicals and ROS produced by radiolysis of water with gamma-or X-rays.
- Referring to the drawings and in particular to
Fig. 1a , a disposable blood anaerobic storage system is shown and referenced usingreference numeral 10. - The blood storage system includes an oxygen/carbon dioxide depletion device 100 (OCDD 100), an anaerobic
blood storage bag 200 and anadditive solution bag 300.OCDD 100 removes oxygen and/or carbon dioxide from red blood cells traveling through it. The system also contains aleuko reduction filter 400. Components conventionally associated with the process of blood collection are aphlebotomy needle 410, ablood collection bag 420 containing an anti-coagulant and abag 430 containing plasma. Tubing can connect the various components of theblood storage system 10 in various configurations (one instance shown).Tube 440 connectscollection bag 420 withleuko reduction filter 400.Tube 441 connectsadditive solution bag 300 withcollection bag 420.Tube 442 connectsplasma bag 430 withcollection bag 420.Tube 443 connectsleukoreduction filter 400 withOCDD 100.Tube 414 connectsOCDD 100 withblood storage bag 200.Blood storage system 10 is preferably a single-use, disposable, low cost system. As filtered and oxygen or oxygen and carbon dioxide depleted blood passes fromOCDD 100 toblood storage bag 200. Blood stored inbag 200 will be gamma or X-ray irradiated during storage viadevice 453.Bag 200 containing oxygen depleted or oxygen and carbon dioxide depleted RBC is placed intodevice 453 and exposed to gamma or X-ray radiation. - For reference only, pre-anaerobic blood stored in
collection bag 421 can be gamma and/or X-ray irradiated viadevice 445 before passing throughOCDD 100 and stored inbag 200, as shown inFig. 1b . InFig. 1b for reference,bag 420 could also be gamma and/or X-ray irradiated in anirradiating device 445 prior to passing throughleukoreduction filter 400. - Oxygen or oxygen/carbon
dioxide depletion device 100 removes the oxygen from collected RBCs prior to the RBCs being stored inblood storage bag 200. The oxygen content in RBCs must be depleted from oxy-hemoglobin because more than 99% of such oxygen is hemoglobin-bound in venous blood. Preferably, the degree of oxygen saturation is to be reduced to less than 4% within 48 hours of blood collection. The oxygen depletion is preferably accomplished at room temperature. The affinity of oxygen to hemoglobin is highly dependent on the temperature, with a p50 of 26 mmHg at 37° C dropping to -4 mmHg at 4° C. Furthermore, this increase in O2 affinity (Ka) is mainly due to reduction in O2 release rate (k-off), resulting in an impractically low rate of oxygen removal once RBC is cooled to 4° C. Thus, it places a constraint on oxygen stripping such that it may be preferable to accomplish it before RBC are cooled to storage temperatures of 1° C to 6° C. - In addition to oxygen depletion, carbon dioxide depletion has the beneficial effect of elevating DPG levels in red blood cells. Carbon dioxide exists inside RBCs and in plasma in equilibrium with HCO3 -ion (carbonic acid). Carbon dioxide is mainly dissolved in RBC/plasma mixture as carbonic acid and rapid equilibrium between CO2 and carbonic acid is maintained by carbonic anhydrase inside RBC. Carbon dioxide is freely permeable through RBC membrane, while HCO3 - inside RBC and plasma is rapidly equilibrated by anion exchanger (band 3) protein. When CO2 is removed from RBC suspension, it results in the known alkalization of RBC interior and suspending medium. This results from removal of HCO3 - inside and outside RBC; cytosolic HCO3 - is converted to CO2 by carbonic anhydrase and removed, while plasma HCO3 - is removed via anion exchange inside RBC. Higher pH inside RBC is known to enhance the rate of glycolysis and thereby increasing ATP and DPG levels. ATP levels are higher in Ar/CO2 (p<0.0001). DPG was maintained beyond 2 weeks in the Argon purged arm only (p<0.0001). Enhanced glycolysis rate is also predicted by disinhibition of key glycolytic enzymes via metabolic modulation and sequesterization of cytosolic-free DPG upon deoxygenation of hemoglobin as a result of anaerobic condition. DPG was lost at the same rate in both control and Ar/CO2 arms (p=0.6) despite thorough deoxygenation of hemoglobin, while very high levels of ATP were achieved with OFAS3 additive (
Figs. 12a-12d ). - Referring to the drawings, and in particular to
Fig. 2a , another disposable blood anaerobic storage system is shown and referenced usingreference numeral 500. The anaerobic conversion system includes an oxygen or oxygen/carbon dioxide depletion device 515 (OCDD) and an anaerobicblood storage bag 528.OCDD 515 removes oxygen or oxygen and carbon dioxide from red blood cells traveling through it. Tubing connects the various components of theblood storage system 500.Tube 512 connects to RBC concentrate prepared by using an additive solution (e.g., AS1, AS3, AS5, SAGM, MAPS, etc.) and storing inbag 528 by passing aforementioned RBC concentrate fromcollection bag 510 throughOCDD 515.Tubes connect OCDD 515 withblood storage bag 528.Blood storage system 500 is preferably a single-use, disposable, low cost system. Oxygen and/or carbon dioxide depleted blood is gamma or X-ray inblood storage bag 528 via device 553 and subsequently stored for later transfusion. - For reference only, blood in
collection bag 510 may be gamma- or X-ray irradiated viadevice 551 prior to oxygen or oxygen and carbon dioxide depletion and low temperature storage, as shown inFig. 2b. Fig. 2b applies for reference to the scenario in whichblood bag 510 contains older, for example 2 day old blood, that is then irradiated and depleted of oxygen or oxygen and or carbon dioxide, and stored. - Referring to
Fig. 3 , an oxygen or oxygen/carbon dioxide depletion device (OCDD) 101 contains anoxygen sorbent 110.OCDD 101 is adisposable cartridge 105 containingoxygen sorbent 110 and a series ofhollow fibers 115.Oxygen sorbent 110 is a mixture of non-toxic inorganic and/or organic salts and ferrous iron or other materials with high reactivity toward oxygen.Oxygen sorbent 110 is made from particles that have significant absorbing capacity for O2 (more than 5 ml O2/g) and can maintain the inside ofcartridge 105 to less than 0.01% which corresponds to P02 less than 0.08 mmHg.Oxygen sorbent 110 is either free or contained in an oxygen permeable envelope.OCDD 101 of the present disclosure must deplete approximately 100 mL of oxygen from a unit of blood. - After oxygen and, optionally, carbon dioxide have been stripped from RBCs in the OCDD of
Fig. 3 , RBCs are stored in ablood storage bag 200. The oxygen content of RBC suspended inadditive solution 300 must be reduced to equal to or less than 4% SO2 before placing them in refrigerated storage. Further, oxygen depleted RBC must be kept in an anaerobic state and low carbon dioxide state throughout entire storage duration. - RBCs pass through an oxygen permeable film or membrane, that may be formed as
hollow fibers 115 ofFig. 3 . The membrane or films may be constructed in a flat sheet or hollow fiber form. The oxygen permeable films can be non porous materials that are capable of high oxygen permeability rates (polyolefins, silicones, epoxies, polyesters, etc.) and oxygen permeable membranes are hydrophobic porous structures. These may be constructed of polymers (e.g., polyolefins, Teflon, PVDF, or polysulfone) or inorganic materials (e.g., ceramics). Oxygen depletion takes place as RBC pass throughhollow fibers 115. Oxygen permeable films or oxygen permeable membranes may be extruded into sheets orhollow fibers 15. Accordingly,hollow fibers 115 and sheets may be used interchangeably. OCDD provides a simple structure having a large surface area to remove oxygen and maintain constant flow of blood therethrough. The oxygen depletion or removal is accomplished by irreversible reaction of ferrous ion inoxygen sorbent 110 with ambient oxygen to form ferric oxide.OCDD 101 does not need agitation for oxygen removal and can be manufactured easily to withstand centrifugation as part of a blood collection system as necessary. - Referring to
Figs. 7a through 7c andFigs. 8a through 8c , examples of flushing depletion devices are disclosed. The depletion devices function to deplete, O2 and CO2, or O2 alone, or O2 with specific levels of CO2 by supplying appropriate composition of flushing gas. Gases appropriate for depletion devices are, for example, Ar, He, N2, Ar/CO2, or N2/CO2. -
Figs. 9a through 9c and10a through 910c , also disclose scavenging depletion devices. Depletion takes place with the use of scavengers or sorbents and without the use of external gases. In both types of depletion devices however, carbon dioxide depletion in conjunction with oxygen depletion is effective to enhance DPG and ATP, respectively, prior to storage in blood storage bags. - Referring to
Figs. 7a through 7c , adepletion device 20 is shown.Depletion device 20 includes a plurality offibers 25, approximately 5000 in number, through which red blood cells flow. Plurality offibers 25 are surrounded by aplastic cylinder 30. Plastic cylinder orcartridge 30 contains agas inlet 35 and agas outlet 40 through which a flushing gas or a combination of flushing gases, such as those mentioned above, are supplied to remove carbon and/or oxygen from blood. Specifications fordepletion device 20 are shown in Table 1 below at second column.Table 1 Prototype Specification External Gas Pathways External Gas Pathways Prototype Serial #: Device 20Device 45Fiber Type: Celgard 200/150-66FP I Celgard 200/150-66F PI Number of Fibers: 5000 5000 Active Length of Fibers (cm): 13 28 Fiber OD (microns): 200 200 Fiber ID (microns): 150 150 Total Length of Fibers 15 30 Active Fiber Surface Area (m2): 0.4084 0.8796 - Referring to
Figs. 8a through 8c , adepletion device 45 is shown.Depletion device 45, likedevice 20 ofFigs. 7a to 7c , includes a plurality offibers 50, approximately 5000 in number, through which red blood cells flow. Plurality offibers 50 are surrounded by aplastic cylinder 55.Plastic cylinder 55 contains agas inlet 60 and agas outlet 65 through which a gas or a combination of gases, such as those mentioned above are supplied to remove oxygen or oxygen and carbon dioxide from blood. Specifications fordepletion device 45 are shown in Table 1 above in the third column. The active surface area of depletion ofdevice 45 is twice that ofdevice 20 becausedevice 45 is twice as long asdevice 20. -
Figs. 9a through 9c disclose adepletion device 70 having a core 75 containing scavenging materials for either O2, or both O2 and CO2.Core 75 is packed by a gas permeable film with very low liquid permeability.Hollow fibers 80 are wound aroundcore 75, and aplastic cylinder 82 contains and envelopes hollowfibers 80. In this particular instance, the active surface area for depletion is approximately 0.8796m2 as shown in Table 2 below at the second column.Table 2 Prototype Specification Center Core 125 grams Sorbent 10 individual Bundles 200 grams SorbentPrototype Serial #: Device 70Device 85Fiber Type: Celgard 200/150-66FP1 Celgard 200/150-66FP1 Number of Fibers: 5000 5000 Active Length of Fibers 13 28 Fiber OD (microns): 200 200 Fiber ID (microns): 150 150 Total Length of Fibers 15 30 Active Fiber Surface Area (m2): 0.8796 0.8796 -
Figs. 10a through 10c disclose adepletion device 85 containingfiber bundles 87 enclosed in gas permeable film with very low liquid permeability. Fiber bundles 87 are surrounded byscavenger materials 89 for either O2 or both O2 and CO2. Fiber bundles 87 andscavenger materials 89 are contained within aplastic cylinder 90. The active surface area for depletion is approximately 0.8796m2 as shown in Table 2 above at the third column. -
Fig. 11 is a plot of the performance of flushingdepletion devices depletion devices Fig. 11 was plotted using the following conditions: Hematocrit, 62% (pooled 3 units of pRBC), and 21°C at various head heights to produce different flow rates. Oxygen/carbon dioxide scavenger (Multisorb Technologies, Buffalo, NY) was activated with adding 5% and 12% w/w water vapor for device 79 anddevice 85, respectively. Data are plotted with flow rate (g RBC suspension per min) vs. pO2 (mmHg). - In the oxygen/carbon dioxide depletion devices disclosed herein, a plurality of gas permeable films/membranes may be substituted for the plurality of hollow fibers. The films and fibers may be packed in any suitable configuration within the cartridge, such as linear or longitudinal, spiral, or coil, so long as they can receive and convey red blood cells.
-
Fig. 11 shows that lowest oxygen saturation is achieved usingdevices Device 45 exhibits a larger active surface area exposed to gases along length offibers 50.Device 85 also has a long surface area of exposure to scavenging materials.Device 85 hasbundles 87 surrounded by scavengingmaterials 89. The space occupied by scavengingmaterials 89 betweenbundles 87 promotes dispersion of oxygen and carbon dioxide from red blood cells contained infiber bundles 87, thus aiding scavenging of oxygen and carbon dioxide from red blood cells. - A further use of the depletion devices is to add back oxygen and or carbon dioxide prior to transfusion by flushing with pure oxygen or air. This use is for special cases, such as massive transfusions, where the capacity of the lung to re-oxygenate transfused blood is not adequate, or sickle cell anemia.
- Similarly, depletion devices can be used to obtain intermediate levels or states of depletion of oxygen and carbon dioxide depending needs of the patient to obtain optimal levels in the transfused blood depending upon the patients needs.
- Referring to
Fig. 4 , ablood storage bag 200 according to the present disclosure is provided.Blood bag 200 has an inner blood-compatible bag 250 (preferably polyvinyl chloride (PVC)), and an outerbarrier film bag 255. The material ofbag 250 is compatible with RBCs. Disposed betweeninner bag 250 and outer oxygenbarrier film bag 255 is a pocket that contains an oxygen/carbon dioxide sorbent 110.Barrier film bag 255 is laminated to the entire surface ofinner bag 250.Sorbent 110 is contained in asachet 260, which is alternately referred to as a pouch or pocket.Sorbent 110 is optimally located betweentubing 440 that leads into and frombag 200, specifically between inner bag and outer oxygenbarrier film bag 255. This location will ensure that oxygen disposed between these two bags will be scavenged or absorbed. Oxygen sorbent is ideally located in a pouch orpocket 260 and not in contact with RBCs. Oxygen sorbent may also be combined with CO2 scavengers or sorbents, enablingsorbent 110 to deplete both oxygen and carbon dioxide at the same time. - Referring to
Figs. 5a and 5b ,blood storage bags 201 and 202 are configured to store RBCs for extended storage periods of time. Innerblood storage bags 205 are preferably made from DEHP-plasticized PVC and are in contact with RBCs. DEHP-plasticized PVC is approximately 200 fold less permeable to oxygen compared to silicone. However, PVC is insufficient as an oxygen barrier to maintain the anaerobic state of RBCs throughout the storage duration. Therefore,blood storage bags 201 and 202 are fabricated with outer transparent oxygen barrier film 206 (e.g., nylon polymer) laminated to the outer surfaceinner blood bag 205. This approach, as well as one shown inFig. 3 , uses accepted PVC for blood contact surface (supplying DEHP for cell stabilization) at the same time prevents oxygen entry into the bag during extended storage. - In
Fig. 5a , asmall sachet 210 containing oxygen/carbon dioxide sorbent 110 enveloped in oxygen-permeable, RBC compatible membrane is enclosed inside oflaminated PVC bag 205 and in contact with RBCs.Small sachet envelope 210 is preferably made from a silicone or siloxane material with high oxygen permeability of biocompatible material.Sachet envelope 210 has a wall thickness of less than 0.13 mm thickness ensures that O2 permeability ceases to become the rate-limiting step.PVC bag 205 may also contain carbon dioxide scavengers. - Referring to
Fig. 5b , bag 202 has a similar configuration to bag 201 ofFig. 4a . However, bag 202 has alarge sorbent 215 enclosed inside ofPVC bag 205.Large sorbent 215 preferably has a comb-like configuration to rapidly absorb oxygen during extended storage. The benefit of laminated bags ofFigs. 4a and 4b is that once RBCs are anaerobically stored in bags, no further special handling is required. Similarly, bag 202 may contain carbon dioxide scavenger to provide carbon dioxide-scavenging in addition to oxygen-scavenging capability. - Referring to the disclosures of
Figs. 6a and 6b , RBCs are stored insecondary bags Secondary bags Secondary bags - Referring to
Fig. 6a , a small oxygen/carbon dioxide sorbent 310 is disposed between a PVC barrier bag 305 andsecondary bag 306 to remove slowly diffusing oxygen.Fig. 6a is similar to the preferred disclosureof the blood bag ofFig. 4 except thatsecondary bag 306 is separate from and not bonded to bag 305 in this instance. PVC bag 305 including ports are enclosed in secondary barrier bag 305.Oxygen sorbent 310 may optionally contain carbon dioxide scavengers to provide both oxygen and carbon dioxide scavenging capability. - Referring to
Fig. 6b , asecondary bag 302 contains alarge sachet 325 inside of PVC bag 320.Sachet 325 is filled with either oxygen or oxygen/carbon dioxide sorbent 110.Sachet 325 is a molded element with surface texture to increase the surface area.Sachet 325 has a comb-like geometry for rapid oxygen or oxygen/carbon dioxide depletion.Sachet 325 acts rapidly to strip oxygen or oxygen/carbon dioxide from RBCs prior to refrigeration and storage of RBCs in place of OCDD ofFig. 3 . However, with this configuration, agitation is necessary, therefore sachet 325 must possess a large surface area, high oxygen or oxygen/carbon dioxide permeability and mechanical strength to withstand centrifugation step during component preparation and the prolonged storage.Sachet 325 is preferably made from materials such as 0.15 mm thick silicone membrane with surface texture to increase the surface area.Sachet 325 may be made from materials such as PTFE or other fluoropolymer.Sachet 325 may have a rectangular shape such, such as, for example, a 4"X 6" rectangle, although other sizes are possible, for the anaerobic maintenance.Sachet 325 may contain carbon dioxide scavengers in addition to oxygen scavengers to provide oxygen and carbon dioxide scavenging capability. - The disclosures of
Figs. 6a and 6b are easily made from off-shelf components except forsachet 325 ofFig. 6b . In order to access RBCs for any testing,secondary bags - In
Figs. 5a, 5b ,6a and 6b , the PVC bag is preferably formed with the oxygen barrier film, such as a SiO2 layer formed with the sol-gel method. A portion of the sheet material will be sealed on standard heat sealing equipment, such as radio frequency sealers. Materials options may be obtained in extruded sheets and each tested for oxygen barrier, lamination integrity, and seal strength/integrity. - For each of the several disclosures addressed above, an additive solution from
bag 300 is provided prior to stripping oxygen and carbon dioxide from the RBCs is used. Theadditive solution 300 preferably contains the following composition adenine 2mmol/L;glucose 110 mmol/L;mannitol 55 mmol/L; NaCI 26mmol/L; Na2HPO4 12mmol/L citric acid and a pH of 6.5.Additive solution 300 is preferably an acidic additive solution OFAS3, although other similar additive solutions could also be used that are shown to enhance oxygen/carbon dioxide -depleted storage. OFAS3 has shown enhanced ATP levels and good in vivo recovery as disclosed herein. While OFAS3 is a preferred additive solution, other solutions that offer similar functionality could also be used. Alternatively, additive solutions used currently in the field, such as AS1, AS3, AS5, SAGM, and MAPS can also be used. Additive solutions help to prevent rapid deterioration of RBCs during storage and are typically added prior to RBCs being made anaerobic. - Additionally, we envision that the OCDD and
storage bags leuko reduction filter 400 inFig. 1a ). - It is within the scope of the present disclosure to remove oxygen from the RBCs or to strip oxygen and carbon dioxide from the blood prior to storage in the storage bags. An oxygen scavenger can be used to remove the oxygen from the RBCs prior to storage in the blood bags. As used herein, "oxygen scavenger" is a material that irreversibly binds to or combines with oxygen under the conditions of use. For example, the oxygen can chemically react with some component of the material and be converted into another compound. Any material where the off-rate of bound oxygen is zero can serve as an oxygen scavenger. Examples of oxygen scavengers include iron powders and organic compounds. The term "oxygen sorbent" may be used interchangeably herein with oxygen scavenger. As used herein, "carbon dioxide scavenger" is a material that irreversibly binds to or combines with carbon dioxide under the conditions of use. For example, the carbon dioxide can chemically react with some component of the material and be converted into another compound. Any material where the off-rate of bound carbon dioxide is zero can serve as a carbon dioxide scavenger. The term "carbon dioxide sorbent" may be used interchangeably herein with carbon dioxide scavenger. For example, oxygen scavengers and carbon dioxide scavengers are provided by Multisorb Technologies (Buffalo, NY) or Mitsubishi Gas Chemical Co (Tokyo, Japan). Oxygen scavengers may exhibit a secondary functionality of carbon dioxide scavenging. Such materials can be blended to a desired ratio to achieve desired results.
- Carbon dioxide scavengers include metal oxides and metal hydroxides. Metal oxides react with water to produce metal hydroxides. The metal hydroxide reacts with carbon dioxide to form water and a metal carbonate. For example, if calcium oxide is used, the calcium oxide will react with water that is added to the sorbent to produce calcium hydroxide
CaO + H2O→Ca(OH)2.
- The calcium hydroxide will react with carbon dioxide to form calcium carbonate and water.
Ca(OH)2 + CO2→CaCO3 + H2O.
- It will be appreciated that scavengers can be incorporated into storage receptacles and bags in any known form, such as in sachets, patches, coatings, pockets, and packets.
- If oxygen removal is completed prior to introduction of the RBCs to the blood storage device, then it can be accomplished by any method known in the art. For example, a suspension of RBCs can be repeatedly flushed with an inert gas (with or without a defined concentration of carbon dioxide), with or without gentle mixing, until the desired oxygen and or carbon dioxide content is reached or until substantially all of the oxygen and carbon dioxide has been removed. The inert gas can be argon, helium, nitrogen, mixtures thereof, or any other gas that does not bind to the hememoiety of hemoglobin.
- The OCDDs and various storage bags of the present disclosure can be used in varying combinations. For example,
OCDD 101 ofFig. 3 can be used with blood bag ofFig. 4 , 201 ofFig. 5a or 301 ofFig. 6a . When oxygen is depleted by in-bag sachet 215 ofFig. 6b , it can be stored as inFig. 6b or oxygen/carbon dioxide -depleted content transferred to the final storage bag such asFig. 4 ,Fig. 5a orFig. 6a for extended storage. Other combinations and configurations are fully within the scope of the present disclosure. - The present disclosure also provides another description of a blood storage device. The device is a sealed receptacle adapted to retain and store red blood cells. The receptacle has walls formed from a laminate. The laminate has (a) an outer layer of a material substantially impermeable to oxygen or oxygen and carbon dioxide, (b) an inner layer of a material compatible with red blood cells, and (c) an interstitial layer between the outer layer and the inner layer. The interstitial layer is of a material having admixed therein an amount of an oxygen scavenger or an oxygen/carbon dioxide scavenger. The layers preferably take the form of polymers. A preferred polymer for the outer layer is nylon. A preferred polymer for inner layer is PVC. The polymer of the interstitial layer should provide effective adhesion between the inner and outer layers and provide effective admixture of oxygen scavengers or oxygen/carbon dioxide scavengers therein. Useful polymers for the interstitial layer include, for example, olefin polymers, such as ethylene and propylene homopolymers and copolymers, and acrylic polymers.
- The present disclosure also provides another description of a blood storage system. The system has a collection bag for red blood cells; a unitary device for depleting oxygen or oxygen and carbon dioxide and reducing leukocytes and/or platelets from red blood cells; a storage bag for red blood cells; and tubing connecting the collection bag to the unitary device and the unitary device to the storage bag. A feature of this disclosure is that the functions of depleting oxygen or oxygen and carbon dioxide and reducing leukocytes and/or platelets from red blood cells are combined into a single, unitary device rather than require separate devices. For instance, unitary device can take the form of a single cartridge. Leukocyte and/or platelet reduction is typically carried out by passing red blood cells through a mesh. In this disclosure, a mesh can be incorporated into either the flushing or the scavenging oxygen or oxygen/carbon dioxide depletion device disclosed herein. The mesh is preferably located within the device so that leukocyte and/or platelet reduction takes place prior to the onset of flushing or scavenging.
- The following are examples of the present disclosure and are not to be construed as limiting.
-
Figs. 12a through 12h show the results of a 3-arm study showing: a control (aerobic OFAS3 with no O2 or CO2 depletion), anaerobic OFAS3 (both O2 and CO2 depleted with pure Ar), and O2 only depleted with 95% Ar and 5% CO2 (CO2 is not depleted). - Whole blood was collected into CP2D (Pall), centrifuged 2KxG for 3 minutes, plasma removed, and additive solution AS-3 (Nutricel, Pall), or experimental OFAS3 added. The unit was evenly divided into 3 600mL bags. 2 bags were gas exchanged x7 with Ar or Ar/CO2, transferred to 150 mL PVC bags and stored 1°C to 6°C in anaerobic cylinders with Ar/H2 or Ar/H2/CO2. One control bag was treated in the same manner without a gas exchange and stored 1°C to 6°C in ambient air. Bags were sampled weekly for up to 9 weeks.
- The plots of
Figs. 12a ,12c ,12e and12g : use the additive solution OFAS3 (200mL; experimental, proprietary) and the plots ofFigs 12b ,12d ,12f and12h , use the AS-3 additive solution. Comparing additive solutions, effects of CO2 depletion on DPG levels were similar. OFAS3 showed higher ATP when oxygen was depleted (±CO2), and O2 depletion alone showed significant enhancement of ATP compared to aerobic control. AS-3 additive exhibited no significant enhancement of ATP when O2 alone was depleted. -
Figs. 12a and 12b : DPG levels during storage. DPG levels were maintained for over 2 weeks, when CO2 was removed in addition to oxygen. -
Fig. 12c : ATP levels during storage with OFAS3. Highest ATP levels were achieved with OFAS3 RBC when O2 only was depleted. For O2/CO2 depletion, intermediate levels of ATP were observed compared to the control while very high DPG levels were attained during first 2.5 weeks. Very high levels of ATP may suggest higher rate of 24-hour post transfusion recovery. Therefore, extent of carbon dioxide and oxygen depletion levels may be adjusted to meet the specific requirement of the recipient. DPG levels can be maintained very high (at the expense of ATP) for purposes of meeting acute oxygen demand of recipient. Conversely, very high ATP levels may allow higher 24-hour recovery rate (lower fraction of non-viable RBC upon transfusion) thereby reducing the quantity of blood needed to be transfused (up to 25% of RBC are non-viable). More importantly, this would benefit chronically transfused patients who may not demand highest oxygen transport efficiency immediately after transfusion (DPG level recovers in body after 8-48 hours) who suffers from toxic iron overloading caused by non-viable RBCs. -
Fig. 12d : ATP levels during storage with AS3. Highest ATP levels were achieved with AS3 RBC when O2 only was depleted. No significant differences in ATP levels where observed with control and O2 depletion alone. -
Figs. 12e and 12f : pH of RBC cytosol (in) and suspending medium (ex). Immediately after gas exchange (day 0), significant rise in pH (in and ex) was observed only when CO2 was depleted together with O2. Rapid rates of pH decline observed with CO2/ O2 depleted samples were caused by higher rates of lactate production (Figs. 12g and 12h ). -
Figs. 12g and 12h : Normalized (to hemoglobin) glucose and lactate levels during storage with OFAS3 and AS3. Higher rates of glucose depletion and lactate productions correspond to high DPG levels observed in panels A and B. Legends for symbols/lines are same for both panels. OFAS3 additive contains similar glucose concentration with x2 volume resulting in higher normalized glucose levels. -
Figs. 12a and12c taken together, suggest that extent of increases (compared to control) of ATP and DPG levels may be adjusted by controlling level of CO2 depletion, when O2 is depleted. Higher glucose utilization and lactate production were observed with enhanced DPG production (Fig. 12g ). This may be also effective with AS3 additive, since similar trend in glucose utilization and lactate production were observed (Fig. 12h ). -
Fig. 13 shows a graph comparing the effect of gamma irradiation on aerobic and anaerobic RBC.Fig. 13 shows an control unit, RBC that are aerobic and not gamma-irradiated (Unit A, black filled solid line), aerobic RBC that are gamma-irradiated (Unit B; control plus gamma irradiation indicated by a filled circle with dotted line) and an anaerobically depleted RBC unit that has been gamma-irradiated (Unit C; Anaerobic + γ, open circle and solid line). Unit B and Unit C are irradiated and Unit A is non-irradiated and aerobic RBC. The constituent of the blood that is being measured is potassium. The amount of leakage of potassium (K+) from RBC that is measured in the storage media is an indicator of health of the RBC. Therefore, in the context of the present application, a greater level of concentration of potassium in RBC storage media, is indicative of a greater level of RBC damage relative to a lower level of concentration of potassium in RBC storage media. -
Fig. 13 indicates that gamma irradiation induced a high rate of K+ leakage during the first week for Unit B and Unit C. K+ leakage rates after days eight and fifteen, were similar for all units. Significantly, the difference between K+ leakage between Unit B and Unit C increases beyond the twenty-second day of storage. The results indicate that this trend could exist for several more days. Accordingly, the use of anaerobic depletion and gamma irradiation may permit the extension of current FDA storage limit of twenty-eight days for anaerobically depleted and gamma irradiated blood prepared after component separation. - Irradiating RBC for immuno-compromised individuals is a necessity. The present results show that irradiated RBC that were also oxygen depleted did not increase K+ leakage rates, an indicator of RBC damage. The benefits of oxygen depleted RBC including increased levels of ATP and DPG-2,3 are not negatively impacted by the irradiation.
- In graph above, four ABO Rh identical units (in AS3 additive, leukoreduced; standard RBC concentrate obtained from American Red Cross) are pooled. The three units were used for above-graphed experiment from the pooled unit after it was sub-divided into 4 fractions within 24 hours of blood collection and stored at 1-6 °C.
Claims (13)
- A method for storing red blood cells comprising:depleting oxygen or oxygen and carbon dioxide from red blood cells, thereby producing oxygen depleted or oxygen and carbon dioxide depleted red blood cells; andirradiating said oxygen depleted or oxygen and carbon dioxide depleted red blood cells with either gamma or X-ray irradiation, thereby producing irradiated oxygen depleted or irradiated oxygen and carbon dioxide depleted red blood cells,wherein said oxygen depleted red blood cells comprise an oxygen-saturation of hemoglobin (SO2) level of less than 20% and said oxygen and carbon dioxide depleted red blood cells comprise a partial pressure of carbon dioxide (pCO2) of less than 10 mmHg.
- The method according to claim 1, further comprising storing said oxygen depleted or oxygen and carbon dioxide depleted red blood cells before or after said irradiating.
- The method according to claim 1, further comprising: leuko-reduction filtering of said red blood cells prior to said step of depleting oxygen or oxygen and carbon dioxide from said red blood cells.
- The method according to claim 1, further comprising: adding an additive solution to said red blood cells prior to said step of depleting oxygen or oxygen and carbon dioxide from said red blood cells.
- The method according to claim 1, wherein said irradiated oxygen depleted or irradiated oxygen and carbon dioxide depleted red blood cells are stored at a temperature from between about 1°C to about 6°C under anaerobic conditions.
- The method according to claim 1, wherein said oxygen depleted or irradiated oxygen and carbon dioxide depleted red blood cells are depleted to an oxygen-saturation of hemoglobin (SO2) level selected from the group consisting of less than 5%, and less than 3% SO2.
- The method according to claim 1, wherein said depleting comprises passing said red blood cells through an oxygen or oxygen and carbon dioxide depletion device comprising:a) a cartridge;
a plurality of gas-permeable films or membranes extending within the cartridge from an entrance to an exit thereof, wherein said plurality of gas-permeable films or membranes are adapted to receiving and conveying red blood cells; and
an amount of an oxygen scavenger or an oxygen and a carbon dioxide scavenger packed within said cartridge and contiguous to and in between said plurality of gas-permeable films or membranes; orb) a receptacle of a solid material having an inlet and an outlet adapted to receiving and expelling a flushing gas and
a plurality of gas-permeable films or membranes extending within said receptacle from an entrance to an exit thereof, wherein said plurality of gas-permeable films or membranes are formed of a material permeable to oxygen and are adapted to receiving and conveying red blood cells. - A composition comprising:irradiated oxygen or oxygen and carbon dioxide depleted red blood cells,wherein said oxygen depleted red blood cells comprise an oxygen-saturation of hemoglobin (SO2) level of less than 20% and said oxygen and carbon dioxide depleted red blood cells comprise an oxygen-saturation of hemoglobin (SO2) level of less than 20% and a partial pressure of carbon dioxide (pCO2) of less than 10 mmHg.
- A sealed receptacle adapted to retain and store red blood cells comprising irradiated oxygen or oxygen and carbon dioxide depleted red blood cells according to claim 8, wherein said sealed receptacle comprises:
walls formed from a laminate comprising:an outer layer of a material substantially impermeable to oxygen or oxygen and carbon dioxide;an inner layer of a material compatible with red blood cells; andan interstitial layer between said outer layer and said inner layer,wherein the interstitial layer is of a material having admixed therein an oxygen or oxygen and carbon dioxide scavenger. - The composition according to claim 8, wherein said oxygen-saturation of hemoglobin (SO2) is less than 5% or less than 3% SO2.
- The composition according to claim 8, wherein said partial pressure of carbon dioxide (pCO2) is less than 5 mmHg or less than 1 mmHg.
- The composition according to claim 8, wherein said irradiated red blood cells are depleted of oxygen or oxygen and carbon dioxide using a depletion device comprising:a) a cartridge;
a plurality of gas-permeable films or membranes extending within the cartridge from an entrance to an exit thereof, wherein said plurality of gas-permeable films or membranes are adapted to receiving and conveying red blood cells; and
an amount of an oxygen scavenger or an oxygen and a carbon dioxide scavenger packed within said cartridge and contiguous to and in between said plurality of gas-permeable films or membranes; orb) a receptacle of a solid material having an inlet and an outlet adapted to receiving
and expelling a flushing gas and
a plurality of gas-permeable films or membranes extending within said receptacle from an entrance to an exit thereof, wherein said plurality of gas-permeable films or membranes are formed of a material permeable to oxygen and are adapted to receiving and conveying red blood cells. - The composition according to claim 8, wherein said irradiated oxygen depleted or irradiated oxygen and carbon dioxide depleted red blood cells further comprise a feature selected from the group consisting of reduced leukocytes relative to an untreated blood sample, an absorbed dose of radiation of between 25 Gray (Gy) to 50 Gy, and an acidic additive solution.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19158815.1A EP3539381B1 (en) | 2010-11-05 | 2011-11-04 | Irradiation of red blood cells and anaerobic storage |
EP23162955.1A EP4218412A1 (en) | 2010-11-05 | 2011-11-04 | Irradiation of red blood cells and anaerobic storage |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41068410P | 2010-11-05 | 2010-11-05 | |
PCT/US2011/059372 WO2012061731A1 (en) | 2010-11-05 | 2011-11-04 | Irradiation of red blood cells and anaerobic storage |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19158815.1A Division-Into EP3539381B1 (en) | 2010-11-05 | 2011-11-04 | Irradiation of red blood cells and anaerobic storage |
EP19158815.1A Division EP3539381B1 (en) | 2010-11-05 | 2011-11-04 | Irradiation of red blood cells and anaerobic storage |
EP23162955.1A Division EP4218412A1 (en) | 2010-11-05 | 2011-11-04 | Irradiation of red blood cells and anaerobic storage |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2635114A1 EP2635114A1 (en) | 2013-09-11 |
EP2635114A4 EP2635114A4 (en) | 2014-12-03 |
EP2635114B1 true EP2635114B1 (en) | 2020-04-29 |
Family
ID=46019976
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23162955.1A Pending EP4218412A1 (en) | 2010-11-05 | 2011-11-04 | Irradiation of red blood cells and anaerobic storage |
EP19158815.1A Active EP3539381B1 (en) | 2010-11-05 | 2011-11-04 | Irradiation of red blood cells and anaerobic storage |
EP11838889.1A Active EP2635114B1 (en) | 2010-11-05 | 2011-11-04 | Irradiation of red blood cells and anaerobic storage |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23162955.1A Pending EP4218412A1 (en) | 2010-11-05 | 2011-11-04 | Irradiation of red blood cells and anaerobic storage |
EP19158815.1A Active EP3539381B1 (en) | 2010-11-05 | 2011-11-04 | Irradiation of red blood cells and anaerobic storage |
Country Status (7)
Country | Link |
---|---|
US (1) | US10136635B2 (en) |
EP (3) | EP4218412A1 (en) |
JP (1) | JP5859558B2 (en) |
CA (1) | CA2817106C (en) |
ES (2) | ES2793484T3 (en) |
PT (2) | PT3539381T (en) |
WO (1) | WO2012061731A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3589259A4 (en) * | 2017-03-03 | 2021-01-06 | Rich Technologies Holding Company, LLC | DEVICE FOR THE PRESERVATION OF BLOOD PRODUCTS AND CELL CULTURES IN A GAS MEDIUM UNDER PRESSURE |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2781866C (en) | 2009-10-12 | 2019-12-03 | New Health Sciences, Inc. | Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities |
US9199016B2 (en) | 2009-10-12 | 2015-12-01 | New Health Sciences, Inc. | System for extended storage of red blood cells and methods of use |
US11284616B2 (en) | 2010-05-05 | 2022-03-29 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
CA2781874A1 (en) | 2009-10-12 | 2011-04-21 | New Health Sciences, Inc. | Oxygen depletion devices and methods for removing oxygen from red blood cells |
US12089589B2 (en) | 2009-10-12 | 2024-09-17 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
ES2959120T3 (en) | 2010-08-25 | 2024-02-20 | Hemanext Inc | Method to enhance the quality and survival of red blood cells during storage |
PT3539381T (en) | 2010-11-05 | 2023-09-26 | Hemanext Inc | RED CELL IRADIATION AND ANAEROBIC STORAGE |
CN103702557A (en) | 2011-03-16 | 2014-04-02 | 梅奥医学教育和研究基金会 | Methods and materials for prolonging useful storage of red blood cell preparations and platelet preparations |
US9067004B2 (en) | 2011-03-28 | 2015-06-30 | New Health Sciences, Inc. | Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly |
WO2013006631A1 (en) | 2011-07-05 | 2013-01-10 | New Health Sciences, Inc. | A system for extended storage of red blood cells and methods of use |
AU2012294269B2 (en) | 2011-08-10 | 2016-11-24 | Hemanext Inc. | Integrated leukocyte, oxygen and/or CO2 depletion, and plasma separation filter device |
WO2014134503A1 (en) | 2013-02-28 | 2014-09-04 | New Health Sciences, Inc. | Gas depletion and gas addition devices for blood treatment |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
WO2016145210A1 (en) | 2015-03-10 | 2016-09-15 | New Health Sciences, Inc. | Oxygen reduction disposable kits, devices and methods of use thereof |
KR102661405B1 (en) * | 2015-04-23 | 2024-04-25 | 헤마넥스트 인코포레이티드 | Anaerobic Blood Storage Container |
MX2017014812A (en) | 2015-05-18 | 2018-05-11 | New Health Sciences Inc | Methods for the storage of whole blood, and compositions thereof. |
WO2017205590A2 (en) * | 2016-05-27 | 2017-11-30 | New Health Sciences, Inc. | Anaerobic blood storage and pathogen inactivation method |
JP7457786B2 (en) * | 2019-07-22 | 2024-03-28 | テルモ株式会社 | Blood Bag System |
WO2022210224A1 (en) * | 2021-03-29 | 2022-10-06 | 国立大学法人新潟大学 | Cell preparation production method and hypoxic stimulation container employed therefor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003103390A1 (en) * | 2002-06-07 | 2003-12-18 | Promethean Lifesciences, Inc. | Sterilization, stabilization and preservation of functional biologics |
WO2011046841A1 (en) * | 2009-10-12 | 2011-04-21 | New Health Sciences, Inc. | Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities |
Family Cites Families (304)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3064647A (en) | 1957-06-13 | 1962-11-20 | Baxter Laboratories Inc | Blood component separation method and apparatus |
US3361041A (en) | 1964-01-13 | 1968-01-02 | Equitable Paper Bag Co | Method and apparatus for making gusseted header bags |
FR1455087A (en) | 1964-05-08 | 1966-04-01 | Schwarz Biores | Blood preservation process |
US3942529A (en) | 1967-02-01 | 1976-03-09 | Investrop A.G. | Package and method for storing blood |
US3668837A (en) | 1970-02-13 | 1972-06-13 | Pall Corp | Separator of the semipermeable membrane type |
US3668838A (en) | 1970-12-07 | 1972-06-13 | Dalph C Mcneil | Flash economizer |
US3803810A (en) | 1972-05-01 | 1974-04-16 | Pall Corp | Liquid-gas separator and filter |
US3910841A (en) | 1974-04-02 | 1975-10-07 | William G Esmond | Stacked exchange device |
US4131200A (en) | 1976-07-06 | 1978-12-26 | Union Carbide Corporation | Thermoplastic blood bag |
US4082509A (en) | 1976-08-05 | 1978-04-04 | Dow Corning Corporation | Method of storing blood and a blood storage bag therefor |
US4086924A (en) | 1976-10-06 | 1978-05-02 | Haemonetics Corporation | Plasmapheresis apparatus |
SE421999B (en) | 1977-10-17 | 1982-02-15 | Gambro Dialysatoren | DEVICE FOR DIFFUSION AND / OR FILTRATION OF THE SUBSTANCE BETWEEN TWO FLUIDS THROUGH SEMIPERMEABLE MEMBRANE, WHICH DEVICE INCLUDES PARALLEL CONNECTED CIRCUITS INCLUDING SERIAL CONNECTED CHAMBERS |
US4370160A (en) | 1978-06-27 | 1983-01-25 | Dow Corning Corporation | Process for preparing silicone microparticles |
US6150085A (en) | 1998-09-16 | 2000-11-21 | The United States Of America As Represented By The Secretary Of The Army | Prolonged storage of red blood cells and composition |
US6447987B1 (en) | 1978-09-09 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Prolonged storage of red blood cells |
US4222379A (en) | 1978-10-26 | 1980-09-16 | Baxter Travenol Laboratories, Inc. | Multiple blood bag having plasticizer-free portions and a high blood component survival rate |
GB2035093B (en) | 1978-10-26 | 1983-01-12 | Baxter Travenol Lab | Medical articles made of blood compatible polymers |
US4228032A (en) | 1978-11-06 | 1980-10-14 | Dow Corning Corporation | Method of storing blood and a blood storage bag therefore |
US4342723A (en) | 1978-11-24 | 1982-08-03 | Shin-Etsu Polymer Co., Ltd. | Gas-exchange sheet members |
US4256692A (en) | 1979-02-01 | 1981-03-17 | C. R. Bard, Inc. | Membrane oxygenator |
US4253458A (en) | 1979-03-08 | 1981-03-03 | Baxter Travenol Laboratories, Inc. | Method and apparatus for collecting blood plasma |
US4262581A (en) | 1979-05-04 | 1981-04-21 | Kcl Corporation | Method and apparatus for making printed gusset bags |
GB2078171B (en) | 1979-11-02 | 1984-05-02 | Toyo Boseki | Multi-layered vessel and process for producing same |
US4381775A (en) | 1980-02-05 | 1983-05-03 | Takeda Chemical Industries, Ltd. | Method for low pressure filtration of plasma from blood |
US4267269A (en) | 1980-02-05 | 1981-05-12 | Baxter Travenol Laboratories, Inc. | Red cell storage solution |
CA1156641A (en) | 1980-03-17 | 1983-11-08 | Takanari Nawata | Oxygen and carbon dioxide absorbent and process for storing coffee by using the same |
US4314480A (en) | 1980-07-14 | 1982-02-09 | Baxter Travenol Laboratories, Inc. | Venous pressure isolator |
US5382526A (en) | 1980-10-31 | 1995-01-17 | Baxter International Inc. | Blood storage container and material |
US4440815A (en) | 1981-06-29 | 1984-04-03 | Abbott Laboratories | Clear, autoclavable plastic formulation for medical liquid containers |
US4455299A (en) | 1981-11-20 | 1984-06-19 | Baxter Travenol Laboratories, Inc. | Storage of blood platelets |
US4386069A (en) | 1981-12-02 | 1983-05-31 | Baxter Travenol Laboratories, Inc. | Additive solution and method for preserving normal red cell morphology in whole blood during storage |
DE3364674D1 (en) | 1982-04-27 | 1986-08-28 | Wellcome Found | Tricyclic compounds, preparation, use and intermediates |
ZA832943B (en) | 1982-04-27 | 1984-12-24 | Wellcome Found | Tricyclic compounds,preparation use and intermediates |
US5310674A (en) | 1982-05-10 | 1994-05-10 | Bar-Ilan University | Apertured cell carrier |
DE3225408A1 (en) | 1982-07-07 | 1984-01-12 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | AQUEOUS SOLUTION FOR SUSPENDING AND STORING CELLS, ESPECIALLY ERYTHROCYTES |
BE898469A (en) | 1982-12-20 | 1984-03-30 | El Paso Polyolefins | Heat sterilizable polyolefin compositions and articles made therefrom. |
US4670013A (en) | 1982-12-27 | 1987-06-02 | Miles Laboratories, Inc. | Container for blood and blood components |
KR890005278B1 (en) | 1983-01-28 | 1989-12-20 | 미쓰비시가스가가꾸 가부시끼 가이샤 | Oxygen absorbent packet |
US4540416A (en) | 1983-08-18 | 1985-09-10 | El Paso Polyolefins Company | Heat-sterilizable polyolefin compositions and articles manufactured therefrom |
US4859360A (en) | 1983-10-27 | 1989-08-22 | Biosynergy, Inc. | Cholesteric liquid crystal formulations and time/temperature monitoring means |
EP0155003B1 (en) | 1984-03-15 | 1990-07-04 | ASAHI MEDICAL Co., Ltd. | Filtering unit for removing leukocytes |
US5417986A (en) | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
US4831012A (en) | 1984-03-23 | 1989-05-16 | Baxter International Inc. | Purified hemoglobin solutions and method for making same |
DE3582523D1 (en) | 1984-07-16 | 1991-05-23 | Sumitomo Bakelite Co | CONTAINER AND METHOD FOR STORING BLOOD. |
US4585735A (en) | 1984-07-19 | 1986-04-29 | American National Red Cross | Prolonged storage of red blood cells |
US4654053A (en) | 1984-07-27 | 1987-03-31 | University Patents, Inc. | Oxygen sorbent |
US4629544A (en) | 1984-09-24 | 1986-12-16 | Aquanautics Corporation | Apparatus and method for reversibly removing ligands from carriers |
US4568328A (en) | 1984-10-29 | 1986-02-04 | Extracorporeal Medical Specialties, Inc. | Automated photophoresis blood portion control methods and apparatus |
US4748121A (en) | 1984-11-30 | 1988-05-31 | Ppg Industries, Inc. | Porous glass fibers with immobilized biochemically active material |
US4713176A (en) | 1985-04-12 | 1987-12-15 | Hemascience Laboratories, Inc. | Plasmapheresis system and method |
FR2581289A1 (en) | 1985-05-06 | 1986-11-07 | Rgl Transfusion Sanguine Centr | SYNTHETIC SOLUTION FOR THE EXTENDED STORAGE OF ERYTHROCYTA CONCENTRATES |
KR890002855B1 (en) | 1985-06-26 | 1989-08-05 | 미쯔비시 가스 가가구 가부시기가이샤 | Sheet-type deoxide material |
SE448444B (en) | 1985-07-08 | 1987-02-23 | Alfa Laval Food & Dairy Eng | CLOSABLE PHASE AND USE OF THIS |
IT1218450B (en) | 1985-09-24 | 1990-04-19 | Teresa Borgione | IMPROVEMENTS TO OXYGENATORS FOR BLOOD, WITH HOLLOW FIBERS |
US4961928A (en) | 1986-03-19 | 1990-10-09 | American Red Cross | Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets |
JPS62157385U (en) | 1986-03-26 | 1987-10-06 | ||
US4769318A (en) | 1986-06-03 | 1988-09-06 | Ube Industries, Ltd. | Additive solution for blood preservation and activation |
JPS6363616A (en) | 1986-09-04 | 1988-03-22 | Showa Denko Kk | Preservation agent for concentrated erythrocyte liquid and method for preservation |
JPH0326882Y2 (en) | 1986-12-12 | 1991-06-11 | ||
US4880786A (en) | 1987-01-14 | 1989-11-14 | Ube Industries, Ltd. | Additive solution for blood preservation and activation |
US5000848A (en) | 1987-01-28 | 1991-03-19 | Membrex, Inc. | Rotary filtration device with hyperphilic membrane |
DE3722984A1 (en) | 1987-07-11 | 1989-01-19 | Biotest Pharma Gmbh | AQUEOUS SOLUTION FOR SUSPENDING AND STORING CELLS, ESPECIALLY ERYTHROCYTES |
JPH07121340B2 (en) | 1987-07-11 | 1995-12-25 | 大日本インキ化学工業株式会社 | Hollow fiber membrane |
EP0299381B2 (en) | 1987-07-11 | 1999-06-30 | Dainippon Ink And Chemicals, Inc. | Membrane-type artificial lung and method of using it |
JP2700170B2 (en) | 1987-07-11 | 1998-01-19 | 大日本インキ化学工業株式会社 | Membrane oxygenator |
US5192320A (en) | 1987-07-11 | 1993-03-09 | Dainippon Ink And Chemicals Inc. | Artificial lung and method of using it |
US4925572A (en) | 1987-10-20 | 1990-05-15 | Pall Corporation | Device and method for depletion of the leukocyte content of blood and blood components |
US4861867A (en) | 1988-02-03 | 1989-08-29 | Baxter International, Inc. | Purified hemoglobin solutions and method for making same |
US4880548A (en) | 1988-02-17 | 1989-11-14 | Pall Corporation | Device and method for separating leucocytes from platelet concentrate |
JP2685544B2 (en) | 1988-11-11 | 1997-12-03 | 株式会社日立製作所 | Blood filter, blood test method, and blood test apparatus |
US4998990A (en) | 1988-12-20 | 1991-03-12 | The Coca-Cola Company | Collapsible bag with evacuation passageway and method for making the same |
US5229012A (en) | 1989-05-09 | 1993-07-20 | Pall Corporation | Method for depletion of the leucocyte content of blood and blood components |
US5120659A (en) | 1989-06-26 | 1992-06-09 | Mine Safety Appliances Company | Deuterated water test method |
ES2070266T3 (en) | 1989-08-18 | 1995-06-01 | Akzo Nobel Nv | VACCINE AGAINST INFECTION WITH ESCHERICHIA COLI. |
US5152905A (en) | 1989-09-12 | 1992-10-06 | Pall Corporation | Method for processing blood for human transfusion |
US5037419A (en) | 1989-09-21 | 1991-08-06 | Eastman Kodak Company | Blood bag system containing vitamin E |
IL95912A (en) | 1989-10-06 | 1998-08-16 | American Nat Red Cross | Method for prolonging the shelf life or red blood cells |
US5386014A (en) | 1989-11-22 | 1995-01-31 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute |
US5139668A (en) * | 1989-12-27 | 1992-08-18 | Alberta Research Corporation | Hollow fiber bundle element |
SU1718766A1 (en) | 1990-01-30 | 1992-03-15 | Ленинградский научно-исследовательский институт гематологии и переливания крови | Method for preserving the blood erythrocytes |
JP2888590B2 (en) | 1990-03-30 | 1999-05-10 | テルモ株式会社 | Equipment for plasma and packed red blood cell collection |
US6187572B1 (en) | 1990-04-16 | 2001-02-13 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants |
CA2040993C (en) | 1990-04-25 | 2001-08-07 | Yoshiaki Inoue | Oxygen absorbent composition and method of preserving article with same |
US6077659A (en) | 1990-05-15 | 2000-06-20 | New York Blood Center, Inc. | Vitamin E and derivatives thereof prevent potassium ion leakage and other types of damage in red cells that are virus sterilized by phthalocyanines and light |
US5194158A (en) | 1990-06-15 | 1993-03-16 | Matson Stephen L | Radon removal system and process |
JP2953753B2 (en) | 1990-06-28 | 1999-09-27 | テルモ株式会社 | Plasma collection device |
JPH0474515A (en) | 1990-07-13 | 1992-03-09 | Toray Ind Inc | oxygen absorber |
US5368808A (en) | 1990-10-26 | 1994-11-29 | Kyoraku Co., Ltd. | Blowbag manufacturing method |
EP0509083B1 (en) | 1990-11-07 | 1997-07-16 | Baxter International Inc. | Red blood cell storage solution |
US5208335A (en) | 1991-03-19 | 1993-05-04 | Air Products And Chemicals, Inc. | Reversible oxygen sorbent compositions |
US5789152A (en) | 1991-04-30 | 1998-08-04 | Basil T. Hone | Composition and method for detecting HIV with baculovirus derived vesicles |
WO1993000005A1 (en) | 1991-06-21 | 1993-01-07 | Baxter International Inc. | Method for inactivating pathogens in a body fluid |
US5443743A (en) | 1991-09-11 | 1995-08-22 | Pall Corporation | Gas plasma treated porous medium and method of separation using same |
US5353793A (en) | 1991-11-25 | 1994-10-11 | Oishi-Kogyo Company | Sensor apparatus |
JP3461360B2 (en) * | 1991-11-30 | 2003-10-27 | 旭メディカル株式会社 | Leukocyte removal filter material |
JP3337232B2 (en) | 1991-12-26 | 2002-10-21 | 東レ・ダウコーニング・シリコーン株式会社 | Method for producing powder mixture comprising cured silicone fine particles and inorganic fine particles |
US5356375A (en) | 1992-04-06 | 1994-10-18 | Namic U.S.A. Corporation | Positive pressure fluid delivery and waste removal system |
JP3177713B2 (en) | 1992-04-30 | 2001-06-18 | 科学技術振興事業団 | How to store blood for transfusion or blood products |
US5304487A (en) | 1992-05-01 | 1994-04-19 | Trustees Of The University Of Pennsylvania | Fluid handling in mesoscale analytical devices |
JPH05317413A (en) | 1992-05-20 | 1993-12-03 | Asahi Medical Co Ltd | Sampler for blood component removed leukocyte |
US6248690B1 (en) | 1992-05-26 | 2001-06-19 | Multisorb Technologies, Inc. | Oxygen absorber |
US5529821A (en) | 1992-06-29 | 1996-06-25 | Terumo Kabushiki Kaisha | Container for storing blood or blood component |
DE4229325C2 (en) | 1992-09-02 | 1995-12-21 | Heraeus Instr Gmbh | Culture vessel for cell cultures |
US5328268A (en) | 1992-10-30 | 1994-07-12 | Custom Packaging Systems, Inc. | Bulk bag with restrainer |
SE9301581D0 (en) | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | PROTEIN FORMULATION |
US5427663A (en) | 1993-06-08 | 1995-06-27 | British Technology Group Usa Inc. | Microlithographic array for macromolecule and cell fractionation |
US5744056A (en) * | 1993-07-16 | 1998-04-28 | Amoco Corporation | Oxygen-scavenging compositions and articles |
US5362442A (en) | 1993-07-22 | 1994-11-08 | 2920913 Canada Inc. | Method for sterilizing products with gamma radiation |
IT1260685B (en) | 1993-09-29 | 1996-04-22 | Sorin Biomedica Spa | BLOOD CONTAINMENT DEVICE |
GB2283015B (en) | 1993-10-22 | 1998-05-13 | Chemitreat Pte Ltd | Membrane reactor for the removal of dissolved oxygen from water |
US20010037978A1 (en) | 1999-04-20 | 2001-11-08 | Daryl R. Calhoun | Filter assembly having a flexible housing and method of making same |
CA2143365A1 (en) | 1994-03-14 | 1995-09-15 | Hugh V. Cottingham | Nucleic acid amplification method and apparatus |
ES2128055T3 (en) | 1994-04-20 | 1999-05-01 | Us Army | VACCINE AGAINST GRAM-NEGATIVE BACTERIA INFECTIONS. |
US5617873A (en) | 1994-08-25 | 1997-04-08 | The United States Of America As Represented By The Administrator, Of The National Aeronautics And Space Administration | Non-invasive method and apparatus for monitoring intracranial pressure and pressure volume index in humans |
US6156231A (en) | 1994-09-08 | 2000-12-05 | Multisorb Technologies, Inc. | Oxygen absorbing composition with cover layer |
US5476764A (en) | 1994-09-16 | 1995-12-19 | The Regents Of The University Of California | Method using CO for extending the useful shelf-life of refrigerated red blood cells |
US6045701A (en) | 1994-10-17 | 2000-04-04 | Baxter International Inc. | Method of filtering a fluid suspension with a membrane having a particular coating |
DE4446270C1 (en) | 1994-12-23 | 1996-02-29 | Hewlett Packard Gmbh | Liquid chromatography de-gasifier |
US5730989A (en) | 1995-02-16 | 1998-03-24 | Novavax, Inc. | Oral vaccine against gram negative bacterial infection |
US6288027B1 (en) | 1995-03-23 | 2001-09-11 | Biopure Corporation | Preserving a hemoglobin blood substitute with a transparent overwrap |
US5605934A (en) | 1995-03-23 | 1997-02-25 | Baxter International Inc. | Method of manufacturing and storing solutions |
PT815138E (en) | 1995-03-23 | 2002-12-31 | Biopure Corp | BLOOD SUBSTITUTE OF STABILIZED POLYMERIZED HEMOGLOBIN |
US6610832B1 (en) * | 1995-03-23 | 2003-08-26 | Biopure Corporation | Preserving a hemoglobin blood substitute with a transparent overwrap |
US5691452A (en) | 1995-03-23 | 1997-11-25 | Biopure Corporation | Method for preserving a hemoglobin blood substitute |
US5895810A (en) | 1995-03-23 | 1999-04-20 | Biopure Corporation | Stable polymerized hemoglobin and use thereof |
WO1996029864A1 (en) | 1995-03-24 | 1996-10-03 | Organ, Inc. | Rejuvenating outdated red cells |
DE69634829T2 (en) | 1995-04-13 | 2006-03-23 | Travenol Laboratories (Israel) Ltd. | METHOD AND DEVICE FOR LEUKOCYTE FILTRATION |
US5624794A (en) | 1995-06-05 | 1997-04-29 | The Regents Of The University Of California | Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas |
US5716852A (en) | 1996-03-29 | 1998-02-10 | University Of Washington | Microfabricated diffusion-based chemical sensor |
US6527957B1 (en) | 1995-08-09 | 2003-03-04 | Baxter International Inc. | Methods for separating, collecting and storing red blood cells |
US6042264A (en) | 1995-10-23 | 2000-03-28 | Lifelines Technology, Inc. | Time-temperature indicator device and method of manufacture |
JPH11513909A (en) | 1995-10-23 | 1999-11-30 | ヘマシユア・インコーポレーテツド | Extraluminal plasma separation and exchange device |
US5709472A (en) | 1995-10-23 | 1998-01-20 | Lifelines Technology, Inc. | Time-temperature indicator device and method of manufacture |
US5686304A (en) | 1995-12-15 | 1997-11-11 | Avecor Cardiovascular, Inc. | Cell culture apparatus and method |
US5693230A (en) | 1996-01-25 | 1997-12-02 | Gas Research Institute | Hollow fiber contactor and process |
US5863460A (en) * | 1996-04-01 | 1999-01-26 | Chiron Diagnostics Corporation | Oxygen sensing membranes and methods of making same |
US5698250A (en) | 1996-04-03 | 1997-12-16 | Tenneco Packaging Inc. | Modifield atmosphere package for cut of raw meat |
SE9601348D0 (en) | 1996-04-10 | 1996-04-10 | Pharmacia Ab | Improved containers for parenteral fluids |
US5906285A (en) | 1996-05-10 | 1999-05-25 | Plastipak Packaging, Inc. | Plastic blow molded container |
IT1285393B1 (en) * | 1996-06-04 | 1998-06-03 | Hospal Dasco Spa | FORMULATION OF PLASTIFIED POLYVINYL CLORIDE FOR THE REALIZATION OF COMPONENTS IN BIOCOMPATIBLE MATERIAL, IN PARTICULAR OF LINES |
EP0904844A4 (en) | 1996-06-10 | 2005-08-31 | Nippon Telegraph & Telephone | Two-fluid nozzle and device employing the same nozzle for freezing and drying liquid containing biological substances |
US6808675B1 (en) | 1996-06-25 | 2004-10-26 | Thermogenesis Corp. | Freezing and thawing bag, mold, apparatus and method |
AU725080B2 (en) | 1996-07-09 | 2000-10-05 | Pall Corporation | Multiple element filter |
US6254628B1 (en) | 1996-12-09 | 2001-07-03 | Micro Therapeutics, Inc. | Intracranial stent |
US5876604A (en) | 1996-10-24 | 1999-03-02 | Compact Membrane Systems, Inc | Method of gasifying or degasifying a liquid |
US6358678B1 (en) | 1998-02-11 | 2002-03-19 | The United States Of America As Represented By The Secretary Of The Navy | Applications of reversible crosslinking and co-treatment in stabilization and viral inactivations of erythrocytes |
EP2305110B1 (en) | 1997-03-17 | 2018-04-11 | Adidas AG | Physiologic signs feedback system |
US6482585B2 (en) | 1997-04-16 | 2002-11-19 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Storage and maintenance of blood products including red blood cells and platelets |
US6403124B1 (en) | 1997-04-16 | 2002-06-11 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Storage and maintenance of blood products including red blood cells and platelets |
US6162396A (en) * | 1997-04-26 | 2000-12-19 | The Regents Of The University Of California | Blood storage device and method for oxygen removal |
US6164821A (en) | 1997-05-09 | 2000-12-26 | The Procter & Gamble Company | Flexible, self-supporting storage bag with hinged, framed closure |
US5789151A (en) * | 1997-05-15 | 1998-08-04 | The Regents Of The University Of California | Prolonged cold storage of red blood cells by oxygen removal and additive usage |
JP3516400B2 (en) | 1997-05-20 | 2004-04-05 | ザイムクエスト,インク. | Cell processing system |
IT1293309B1 (en) | 1997-07-09 | 1999-02-16 | Sis Ter Spa | BLOOD TREATMENT EQUIPMENT WITH MEMBRANE EXCHANGE DEVICE |
US6368871B1 (en) | 1997-08-13 | 2002-04-09 | Cepheid | Non-planar microstructures for manipulation of fluid samples |
US6022477A (en) | 1997-11-14 | 2000-02-08 | New Jersey Institute Of Technology | Method and apparatus for isolation purification of biomolecules |
DE19754573A1 (en) | 1997-12-09 | 1999-06-10 | Bayer Ag | Pharmaceutical composition for the treatment of stroke and traumatic brain injury |
AU757403B2 (en) | 1998-03-25 | 2003-02-20 | Cryovac, Inc. | Oxygen scavengers with reduced oxidation products for use in plastic films and beverage and food containers |
US6027623A (en) | 1998-04-22 | 2000-02-22 | Toyo Technologies, Inc. | Device and method for electrophoretic fraction |
US5937617A (en) | 1998-05-01 | 1999-08-17 | Innoflex Incorporated | Pouch with pre-inserted straw |
US6090062A (en) | 1998-05-29 | 2000-07-18 | Wayne State University | Programmable antisiphon shunt system |
US6908553B1 (en) | 1998-07-08 | 2005-06-21 | Baxter International Inc. | Composite membrane with particulate matter substantially immobilized therein |
US20070099170A1 (en) | 1998-07-21 | 2007-05-03 | Navigant Biotechnologies, Inc. | Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate |
US20030215784A1 (en) * | 1998-07-21 | 2003-11-20 | Dumont Larry Joe | Method and apparatus for inactivation of biological contaminants using photosensitizers |
CA2341614C (en) | 1998-08-31 | 2008-11-18 | Walter Reed Army Institute Of Research | Prolonged storage of red blood cells |
JP4638986B2 (en) | 1998-10-16 | 2011-02-23 | テルモ メディカル コーポレイション | Blood processing equipment |
AUPP676898A0 (en) | 1998-10-26 | 1998-11-19 | Noble House Group Pty Ltd | Sampling first in blood collection |
US6413713B1 (en) | 1998-10-30 | 2002-07-02 | Hyperbaric Systems | Method for preserving blood platelets |
CA2287768C (en) | 1998-11-02 | 2004-01-13 | Ahmed Abdoh | Method for automated data collection, analysis and reporting |
US6475147B1 (en) | 1999-01-27 | 2002-11-05 | The United States Of America As Represented By The United States National Aeronautics And Space Administration | Ultrasonic apparatus and technique to measure changes in intracranial pressure |
US6582496B1 (en) | 2000-01-28 | 2003-06-24 | Mykrolis Corporation | Hollow fiber membrane contactor |
US6337026B1 (en) | 1999-03-08 | 2002-01-08 | Whatman Hemasure, Inc. | Leukocyte reduction filtration media |
US6945411B1 (en) | 1999-03-16 | 2005-09-20 | Pall Corporation | Biological fluid filter and system |
US6097293A (en) | 1999-04-15 | 2000-08-01 | Industrial Technology, Inc. | Passive electrical marker for underground use and method of making thereof |
US6210601B1 (en) | 1999-04-21 | 2001-04-03 | Larry A. Hottle | Method of making an oxygen scavenging sealant composition |
ATE288478T1 (en) | 1999-04-30 | 2005-02-15 | Massachusetts Gen Hospital | PRODUCTION OF THREE-DIMENSIONAL VASCULARIZED TISSUE USING TWO-DIMENSIONAL MICRO-Fabricated MOLDS |
US7371400B2 (en) | 2001-01-02 | 2008-05-13 | The General Hospital Corporation | Multilayer device for tissue engineering |
US6387461B1 (en) | 1999-05-06 | 2002-05-14 | Cryovac, Inc. | Oxygen scavenger compositions |
US6629919B2 (en) | 1999-06-03 | 2003-10-07 | Haemonetics Corporation | Core for blood processing apparatus |
US6610772B1 (en) | 1999-08-10 | 2003-08-26 | Eastman Chemical Company | Platelet particle polymer composite with oxygen scavenging organic cations |
US6287284B1 (en) | 1999-09-27 | 2001-09-11 | Npt, Inc. | Silicone bag assembly |
US6703492B1 (en) | 1999-11-09 | 2004-03-09 | Smithkline Beecham Corporation | Staphylococcus epidermidis nucleic acids and proteins |
CN101362058B (en) | 1999-12-08 | 2011-10-12 | 巴克斯特国际公司 | Microporous filter membrane, method of making microporous filter membrane and separator employing microporous filter membranes |
US6315815B1 (en) | 1999-12-16 | 2001-11-13 | United Technologies Corporation | Membrane based fuel deoxygenator |
ATE387950T1 (en) | 2000-03-07 | 2008-03-15 | Mat Adsorption Technologies Gm | MODULE WITH MEMBRANE ELEMENTS IN CROSS-FLOW AND DEAD-END ARRANGEMENT |
CA2405443A1 (en) | 2000-03-31 | 2001-10-11 | Baxter International, Inc. | Systems and methods for collecting leukocyte-reduced blood components, including plasma that is free or virtually free of cellular blood species |
US6468732B1 (en) | 2000-04-04 | 2002-10-22 | Bayer Corporation | Method and long-term stable bicarbonate-containing diluent composition, and storage means therefor, for reducing or reversing aeration induced cell shrinkage and storage induced cell swelling of a whole blood sample |
EP1275891B1 (en) | 2000-04-21 | 2006-01-25 | Kuraray Co., Ltd. | Multilayered tube and medical supply comprising multilayered tube |
US6402818B1 (en) | 2000-06-02 | 2002-06-11 | Celgard Inc. | Degassing a liquid with a membrane contactor |
US6558571B1 (en) | 2000-08-11 | 2003-05-06 | Multisorb Technologies, Inc. | Oxygen-absorbing composition and method |
US7904313B2 (en) | 2000-08-24 | 2011-03-08 | Quintiles, Inc. | Recruiting a patient into a clinical trial |
AU2001295086A1 (en) | 2000-09-27 | 2002-04-08 | Mark W. Bitensky | Cellular diagnostic arrays, methods of using and processes for producing same |
US20080027368A1 (en) | 2000-09-27 | 2008-01-31 | Sorin Group Usa, Inc. | Disposable cartridge for a blood perfusion system |
EP1322352A4 (en) | 2000-09-27 | 2010-06-16 | Sorin Group Usa Inc | Disposable cartridge for a blood perfusion system |
US7604599B2 (en) | 2000-09-29 | 2009-10-20 | New Health Sciences, Inc. | Systems and methods for using dynamic vascular assessment to improve vascular stent placement, application, design and marketing |
US6955648B2 (en) | 2000-09-29 | 2005-10-18 | New Health Sciences, Inc. | Precision brain blood flow assessment remotely in real time using nanotechnology ultrasound |
US6692443B2 (en) | 2000-09-29 | 2004-02-17 | New Health Sciences, Inc. | Systems and methods for investigating blood flow |
US7104958B2 (en) | 2001-10-01 | 2006-09-12 | New Health Sciences, Inc. | Systems and methods for investigating intracranial pressure |
US6494909B2 (en) | 2000-12-01 | 2002-12-17 | Prodesco, Inc. | Endovascular valve |
US6770434B2 (en) | 2000-12-29 | 2004-08-03 | The Provost, Fellows And Scholars Of The College Of The Holy & Undivided Trinity Of Queen Elizabeth Near Dublin | Biological assay method |
US6773670B2 (en) | 2001-02-09 | 2004-08-10 | Cardiovention, Inc. C/O The Brenner Group, Inc. | Blood filter having a sensor for active gas removal and methods of use |
JP2002253936A (en) | 2001-02-28 | 2002-09-10 | Japan Gore Tex Inc | Separation membrane tube and separation membrane module |
US6613280B2 (en) | 2001-03-20 | 2003-09-02 | Therox, Inc. | Disposable cartridge for producing gas-enriched fluids |
US6974447B2 (en) | 2001-04-17 | 2005-12-13 | Baxter International Inc. | High gas barrier receptacle and closure assembly |
CN2502700Y (en) | 2001-05-10 | 2002-07-31 | 张明礼 | Blood collecting device |
US6697667B1 (en) | 2001-05-31 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for locating coronary sinus |
KR100885367B1 (en) | 2001-07-31 | 2009-02-26 | 아사히 가세이 메디컬 가부시키가이샤 | Coating material for leukocyte removal filter |
US7909788B2 (en) | 2001-08-01 | 2011-03-22 | Battelle Memorial Institute | Carbon dioxide removal from whole blood by photolytic activation |
US6682698B2 (en) | 2001-08-23 | 2004-01-27 | Michigan Critical Care Consultants, Inc. | Apparatus for exchanging gases in a liquid |
DE10151343A1 (en) | 2001-10-22 | 2003-05-08 | Vita 34 Ag | Bag system for the cryopreservation of body fluids |
EP1458235A4 (en) * | 2001-11-16 | 2005-04-06 | Hemanext Llc | ADDITIVE SOLUTION FOR BLOOD CONSERVATION |
EP1450604A4 (en) * | 2001-11-16 | 2005-01-12 | Hollinger Digital Inc | METHOD FOR EXTENDING THE PERIOD OF USEFUL STORAGE OF REFRIGERATED RED GLOBLES BY NUTRIENT SUPPLEMENT |
EP1455860B1 (en) | 2001-12-10 | 2011-08-31 | CaridianBCT, Inc. | Method for the leukoreduction of red blood cells |
US20050210141A1 (en) | 2002-01-31 | 2005-09-22 | Telefonaktiebolaget Lm Ericsson (Publ) | Method for providing multiple sdp media flows in a single pop context |
US6761695B2 (en) | 2002-03-07 | 2004-07-13 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Method and apparatus for non-invasive measurement of changes in intracranial pressure |
WO2003078023A1 (en) | 2002-03-14 | 2003-09-25 | Baxter International Inc. | Compound removal device |
JP4498748B2 (en) | 2002-03-19 | 2010-07-07 | インテグリス・インコーポレーテッド | Hollow fiber membrane contactor and process |
US20030183801A1 (en) | 2002-03-28 | 2003-10-02 | Hu Yang | Porous oxygen scavenging material |
US6767466B2 (en) | 2002-04-08 | 2004-07-27 | Teva Medical Ltd. | Leukocyte filter construction |
US6773407B2 (en) | 2002-04-08 | 2004-08-10 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Non-invasive method of determining absolute intracranial pressure |
US20030190272A1 (en) | 2002-04-08 | 2003-10-09 | Dennis Raine | Sterilization containers and methods for radiation sterilization of liquid products |
ATE402723T1 (en) | 2002-04-16 | 2008-08-15 | Gambro Bct Inc | SYSTEM FOR SEPARATING BLOOD COMPONENTS, APPARATUS AND METHOD |
AU2003225174A1 (en) | 2002-04-24 | 2003-11-10 | Gambro, Inc. | Removal of adenine during a process of pathogen reducing blood and blood components |
US6899743B2 (en) | 2002-06-12 | 2005-05-31 | Membrane Technology And Research, Inc. | Separation of organic mixtures using gas separation or pervaporation and dephlegmation |
US6878335B2 (en) | 2002-06-21 | 2005-04-12 | Vital Signs, Inc. | Process of manufacturing a breathing bag and breathing bag manufactured by such process |
US6817979B2 (en) | 2002-06-28 | 2004-11-16 | Nokia Corporation | System and method for interacting with a user's virtual physiological model via a mobile terminal |
JP2004089495A (en) | 2002-08-30 | 2004-03-25 | Terumo Corp | Bag link |
US20080160107A1 (en) | 2002-09-10 | 2008-07-03 | Nitric Biotherapeutics, Inc. | Use of nitric oxide gas to treat blood and blood products |
US7241282B2 (en) | 2002-11-08 | 2007-07-10 | The Brigham And Women's Hospital, Inc. | Compositions and methods for prolonging survival of platelets |
US6899822B2 (en) | 2002-11-18 | 2005-05-31 | Multisorb Technologies, Inc. | Oxygen-absorbing composition |
DE10327988B4 (en) | 2002-12-18 | 2009-05-14 | Alpha Plan Gmbh | Filter module for the treatment of liquids |
ITTO20030039A1 (en) | 2003-01-24 | 2004-07-25 | Fresenius Hemocare Italia Srl | FILTER TO SEPARATE LEUKOCYTES FROM WHOLE BLOOD AND / OR FROM BLOOD-PREPARED PROCEDURES, PROCEDURE FOR FILTER MANUFACTURE, DEVICE AND USE. |
US8828226B2 (en) | 2003-03-01 | 2014-09-09 | The Trustees Of Boston University | System for assessing the efficacy of stored red blood cells using microvascular networks |
US7517453B2 (en) | 2003-03-01 | 2009-04-14 | The Trustees Of Boston University | Microvascular network device |
US20040254560A1 (en) | 2003-06-11 | 2004-12-16 | Coelho Philip H. | Rupture resistant blow molded freezer bag for containing blood products |
US7078100B2 (en) | 2003-08-28 | 2006-07-18 | Cryovac, Inc. | Oxygen scavenger compositions derived from isophthalic acid and/or terephthalic acid monomer or derivatives thereof |
US7754798B2 (en) | 2003-08-28 | 2010-07-13 | Cryovac, Inc. | Oxygen scavenger block copolymers and compositions |
US8070952B2 (en) | 2003-10-03 | 2011-12-06 | Medical Service S.R.L. | Apparatus and method for the treatment of blood |
US7097690B2 (en) | 2003-10-10 | 2006-08-29 | Scimed Life Systems, Inc. | Apparatus and method for removing gasses from a liquid |
US20050085785A1 (en) | 2003-10-17 | 2005-04-21 | Sherwin Shang | High impact strength film and non-pvc containing container and pouch and overpouch |
CA2544612C (en) | 2003-11-24 | 2011-12-20 | Gambro Lundia Ab | Degassing device and end-cap assembly for a filter including such a degassing device |
US20050137517A1 (en) | 2003-12-19 | 2005-06-23 | Baxter International Inc. | Processing systems and methods for providing leukocyte-reduced blood components conditioned for pathogen inactivation |
US7347887B2 (en) | 2003-12-22 | 2008-03-25 | The Boc Group, Inc. | Oxygen sorbent compositions and methods of using same |
US20050139806A1 (en) | 2003-12-24 | 2005-06-30 | Havens Marvin R. | Oxygen scavenger compositions |
US7125498B2 (en) | 2004-02-04 | 2006-10-24 | Multisorb Technologies, Inc. | Oxygen-absorbing compositions and method |
US9314014B2 (en) | 2004-02-18 | 2016-04-19 | University Of Maryland, Baltimore | Compositions and methods for the storage of red blood cells |
JP4579569B2 (en) | 2004-04-16 | 2010-11-10 | 株式会社クレハ | Multi-layer biaxially stretched blow bottle and manufacturing method thereof |
WO2006031385A2 (en) | 2004-08-24 | 2006-03-23 | The General Hospital Corporation | Particle separating devices, systems and methods |
US20060081524A1 (en) | 2004-10-15 | 2006-04-20 | Amitava Sengupta | Membrane contactor and method of making the same |
KR100721054B1 (en) | 2004-11-23 | 2007-05-25 | 주식회사 뉴하트바이오 | Filter module for blood purification and / or blood oxidation, blood purification and blood oxidation method using the same and blood purification device comprising the same |
AU2005322136B2 (en) | 2004-12-23 | 2011-01-06 | Hospira, Inc. | Port closure system for intravenous fluid container |
US20100221697A1 (en) | 2005-01-12 | 2010-09-02 | BioVec Transfusions, LLC | Composition for preserving platelets and method of using and storing the same |
EP1683579A1 (en) | 2005-01-25 | 2006-07-26 | Jean-Denis Rochat | Disposable device for the continuous separation by centrifugation of a physiological liquid |
US7465335B2 (en) | 2005-02-02 | 2008-12-16 | United Technologies Corporation | Fuel deoxygenation system with textured oxygen permeable membrane |
JP2008529550A (en) | 2005-02-17 | 2008-08-07 | ユニバーシティ・オブ・シンシナティ | Compositions and methods for the preservation of red blood cells |
JP3772909B1 (en) | 2005-04-04 | 2006-05-10 | 東洋紡績株式会社 | Blood purifier |
US20060226087A1 (en) | 2005-04-08 | 2006-10-12 | Mission Medical, Inc. | Method and apparatus for blood separations |
CN2780207Y (en) | 2005-04-12 | 2006-05-17 | 浙江科锐生物科技有限公司 | Disposable active carbon blood perfusion device |
EP1879599B1 (en) | 2005-04-20 | 2013-10-16 | Fred Hutchinson Cancer Research Center | Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms |
JP4584018B2 (en) | 2005-05-09 | 2010-11-17 | 日東電工株式会社 | Deaerator |
US7465336B2 (en) | 2005-06-09 | 2008-12-16 | United Technologies Corporation | Fuel deoxygenation system with non-planar plate members |
CN2894710Y (en) | 2006-03-31 | 2007-05-02 | 天津市海河医院 | Medical blood-qi exchanger |
US7763097B2 (en) | 2006-06-08 | 2010-07-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Devices, systems and methods for reducing the concentration of a chemical entity in fluids |
US7517146B2 (en) | 2006-08-30 | 2009-04-14 | Temptime Corporation | Color-retaining excess-temperature exposure indicator |
US7713614B2 (en) | 2006-09-19 | 2010-05-11 | Kuraray Co., Ltd. | Resin composition and multilayer structure |
EP1902740A1 (en) | 2006-09-19 | 2008-03-26 | Maco Pharma S.A. | Blood bag system and process for the inactivation of pathogens in platelet concentrates by use of the blood bag system |
KR20090057271A (en) | 2006-09-25 | 2009-06-04 | 니프로 가부시키가이샤 | Blow Molding Sap Containers of Plastics |
US20080098894A1 (en) | 2006-11-01 | 2008-05-01 | Sabatino Daniel R | Acoustic degassing heat exchanger |
WO2008089337A1 (en) | 2007-01-19 | 2008-07-24 | The Regents Of The University Of Michigan | Compositions and methods for preserving red blood cells |
JP2008253452A (en) | 2007-04-03 | 2008-10-23 | Sekisui Chem Co Ltd | Vacuum blood collection tube |
US8398743B2 (en) | 2007-05-08 | 2013-03-19 | General Electric Company | Methods and systems for reducing carbon dioxide in combustion flue gases |
KR101071402B1 (en) | 2007-09-11 | 2011-10-07 | (주) 비에이치케이 | Apparatus for purifying blood |
EP2252362A1 (en) | 2008-02-07 | 2010-11-24 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Intracorporeal gas exchange devices, systems and methods |
EP2113266A1 (en) | 2008-04-30 | 2009-11-04 | Gambro Lundia AB | Degassing device |
WO2009132839A1 (en) | 2008-04-30 | 2009-11-05 | Gambro Lundia Ab | Hydrophobic deaeration membrane |
JP5560459B2 (en) | 2008-10-17 | 2014-07-30 | 三菱マテリアル株式会社 | Method for synthesizing metal nanoparticles |
US8177884B2 (en) | 2009-05-20 | 2012-05-15 | United Technologies Corporation | Fuel deoxygenator with porous support plate |
US8377172B2 (en) | 2009-06-11 | 2013-02-19 | Georgia Tech Research Corporation | Fiber sorbents |
WO2011014855A2 (en) | 2009-07-31 | 2011-02-03 | University Of Pittsburgh -Of The Commonwealth System Of Higher Education | Removal of oxygen from biological fluids |
JP5605362B2 (en) | 2009-08-04 | 2014-10-15 | 三菱瓦斯化学株式会社 | Container manufacturing method |
US9199016B2 (en) | 2009-10-12 | 2015-12-01 | New Health Sciences, Inc. | System for extended storage of red blood cells and methods of use |
CA2781874A1 (en) | 2009-10-12 | 2011-04-21 | New Health Sciences, Inc. | Oxygen depletion devices and methods for removing oxygen from red blood cells |
JP2011092905A (en) | 2009-10-30 | 2011-05-12 | Japan Gore Tex Inc | Method for manufacturing degassing membrane, envelope-like object, and degassing device using the envelope-like object |
CN106178161B (en) | 2009-12-01 | 2020-12-22 | 艾克塞拉医疗公司 | Method for removing cytokines from blood using surface immobilized polysaccharides |
US20130197420A1 (en) | 2010-01-19 | 2013-08-01 | William H. Fissell, IV | Nanoporous membranes, devices, and methods for respiratory gas exchange |
ES2959120T3 (en) | 2010-08-25 | 2024-02-20 | Hemanext Inc | Method to enhance the quality and survival of red blood cells during storage |
PT3539381T (en) | 2010-11-05 | 2023-09-26 | Hemanext Inc | RED CELL IRADIATION AND ANAEROBIC STORAGE |
US20120219633A1 (en) | 2011-02-28 | 2012-08-30 | Pall Corporation | Removal of immunoglobulins and leukocytes from biological fluids |
WO2012120927A1 (en) | 2011-03-09 | 2012-09-13 | テルモ株式会社 | System for delivering oxygen carrier, oxygenation device for oxygen carrier, and housing for oxygen carrier |
JP6034362B2 (en) | 2011-03-28 | 2016-11-30 | ニュー・ヘルス・サイエンシーズ・インコーポレイテッドNew Health Sciences, Inc. | Method and system for removing oxygen and carbon dioxide during erythrocyte blood processing using an inert carrier gas and manifold assembly |
US9067004B2 (en) | 2011-03-28 | 2015-06-30 | New Health Sciences, Inc. | Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly |
WO2013006631A1 (en) | 2011-07-05 | 2013-01-10 | New Health Sciences, Inc. | A system for extended storage of red blood cells and methods of use |
AU2012294269B2 (en) | 2011-08-10 | 2016-11-24 | Hemanext Inc. | Integrated leukocyte, oxygen and/or CO2 depletion, and plasma separation filter device |
CA2870166C (en) | 2012-04-13 | 2020-07-21 | Ologn Technologies Ag | Secure zone for digital communications |
EP4108331A1 (en) | 2012-05-22 | 2022-12-28 | Hemanext Inc. | Capillary network devices |
US9083010B2 (en) | 2012-07-18 | 2015-07-14 | Nthdegree Technologies Worldwide Inc. | Diatomaceous energy storage devices |
US9057901B2 (en) | 2012-11-29 | 2015-06-16 | Shenzhen China Star Optoelectronics Technology Co., Ltd | Plastic frame, backlight module and liquid crystal display device |
US20140158604A1 (en) | 2012-12-12 | 2014-06-12 | Jacques Chammas | Platelet Storage Container |
WO2014134503A1 (en) | 2013-02-28 | 2014-09-04 | New Health Sciences, Inc. | Gas depletion and gas addition devices for blood treatment |
US20140248005A1 (en) | 2013-03-01 | 2014-09-04 | Stokely-Van Camp, Inc. | Stand-Up Pouch |
US9174771B2 (en) | 2013-03-15 | 2015-11-03 | Sangart, Inc. | Packaging system for preserving a nonoxygenated hemoglobin based oxygen therapeutic product |
WO2014194931A1 (en) | 2013-06-03 | 2014-12-11 | Onderzoeks- En Ontwikkelingsfonds Rode Kruis-Vlaanderen | Pathogen reduction treatment |
WO2016145210A1 (en) | 2015-03-10 | 2016-09-15 | New Health Sciences, Inc. | Oxygen reduction disposable kits, devices and methods of use thereof |
KR102661405B1 (en) | 2015-04-23 | 2024-04-25 | 헤마넥스트 인코포레이티드 | Anaerobic Blood Storage Container |
-
2011
- 2011-11-04 PT PT191588151T patent/PT3539381T/en unknown
- 2011-11-04 US US13/289,722 patent/US10136635B2/en active Active
- 2011-11-04 EP EP23162955.1A patent/EP4218412A1/en active Pending
- 2011-11-04 PT PT118388891T patent/PT2635114T/en unknown
- 2011-11-04 EP EP19158815.1A patent/EP3539381B1/en active Active
- 2011-11-04 CA CA2817106A patent/CA2817106C/en active Active
- 2011-11-04 ES ES11838889T patent/ES2793484T3/en active Active
- 2011-11-04 WO PCT/US2011/059372 patent/WO2012061731A1/en active Application Filing
- 2011-11-04 EP EP11838889.1A patent/EP2635114B1/en active Active
- 2011-11-04 JP JP2013537875A patent/JP5859558B2/en active Active
- 2011-11-04 ES ES19158815T patent/ES2957338T3/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003103390A1 (en) * | 2002-06-07 | 2003-12-18 | Promethean Lifesciences, Inc. | Sterilization, stabilization and preservation of functional biologics |
WO2011046841A1 (en) * | 2009-10-12 | 2011-04-21 | New Health Sciences, Inc. | Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities |
Non-Patent Citations (1)
Title |
---|
P ; AGARWAL ET AL: "Effect of pre-storage gamma irradiation on red blood cells", INDIAN JOURNAL OF MEDICAL RESEARCH NOV, vol. 122, no. 5, 1 January 2005 (2005-01-01), pages 385, XP055464831 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3589259A4 (en) * | 2017-03-03 | 2021-01-06 | Rich Technologies Holding Company, LLC | DEVICE FOR THE PRESERVATION OF BLOOD PRODUCTS AND CELL CULTURES IN A GAS MEDIUM UNDER PRESSURE |
Also Published As
Publication number | Publication date |
---|---|
WO2012061731A1 (en) | 2012-05-10 |
JP2014501501A (en) | 2014-01-23 |
JP5859558B2 (en) | 2016-02-10 |
ES2957338T3 (en) | 2024-01-17 |
EP3539381B1 (en) | 2023-05-24 |
US20120115124A1 (en) | 2012-05-10 |
EP2635114A4 (en) | 2014-12-03 |
US20160242410A9 (en) | 2016-08-25 |
PT2635114T (en) | 2020-06-16 |
PT3539381T (en) | 2023-09-26 |
EP4218412A1 (en) | 2023-08-02 |
EP3539381A1 (en) | 2019-09-18 |
CA2817106C (en) | 2020-08-25 |
US10136635B2 (en) | 2018-11-27 |
EP2635114A1 (en) | 2013-09-11 |
CA2817106A1 (en) | 2012-05-10 |
ES2793484T3 (en) | 2020-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2635114B1 (en) | Irradiation of red blood cells and anaerobic storage | |
US8535421B2 (en) | Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities | |
US9296990B2 (en) | Oxygen depletion devices and methods for removing oxygen from red blood cells | |
CA2840901C (en) | A system for extended storage of red blood cells and methods of use | |
US6162396A (en) | Blood storage device and method for oxygen removal | |
EP4091645A1 (en) | Method for enhancing red blood cell quality and survival during storage | |
US11284616B2 (en) | Irradiation of red blood cells and anaerobic storage | |
US20230180741A1 (en) | DEHP-Free Blood Storage and Methods of Use Thereof | |
US12089589B2 (en) | Irradiation of red blood cells and anaerobic storage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130529 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20141030 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A01N 1/02 20060101AFI20141024BHEP Ipc: C12N 5/02 20060101ALI20141024BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170404 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20190930 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20191203 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1261951 Country of ref document: AT Kind code of ref document: T Effective date: 20200515 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011066578 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 2635114 Country of ref document: PT Date of ref document: 20200616 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20200529 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: HEMANEXT INC. |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20200429 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20200429 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200730 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200829 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2793484 Country of ref document: ES Kind code of ref document: T3 Effective date: 20201116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200729 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1261951 Country of ref document: AT Kind code of ref document: T Effective date: 20200429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011066578 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20210201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201104 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20201130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201130 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230518 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240912 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240909 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20240910 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602011066578 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A01N0001020000 Ipc: A01N0001100000 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20241102 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240910 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NO Payment date: 20241111 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20241025 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20241010 Year of fee payment: 14 Ref country code: ES Payment date: 20241206 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20241201 Year of fee payment: 14 |